UNIVERSITA' degli STUDI di ROMA
TOR VERGATA

FACOLTA' DI SCIENZE MATEMATICHE FISICHE E NATURALI

DOTTORATO DI RICERCA IN IMMUNOLOGIA
XX CICLO
(2004-2007)

Neisseria gonorrhoeae strains of recent isolation in Italy: study of surface-exposed antigens and sera from infected patients

DOTTORANDA: Stefania Starnino

TUTOR: Dr.ssa Paola Stefanelli

COORDINATORE: Prof. Paolo Rossi

Index

1. Introduction

Neisseria gonorrhoeae, the gonococcus, is a Gram negative diplococcus cause of the sexually transmitted disease named gonorrhoea. Citations to the contagious nature of gonococcal infection dates back to biblical times (Lev. 15:1-15-19) and in ancient Chinese writings (Handsfield M, 1990), making gonorrhoea one of the oldest recorded human disease. Hippocrates referred to acute gonorrhoea as "strangury" obtained from the "pleasures of Venus" in the fourth and the fifth centuries B.C. (Sparling PF, 1999). Neisser described the causative agent of gonorrhoea in 1879, and in 1882 Leistikow and Löffler finally cultivated the gonococcus (Sparling PF, 1999).

Today, gonococcal infection remains a major global health problem with increasing infection rates worldwide (Tapsall JW et al, 2001). The World Health Organization (WHO) estimates more than 60 million new cases of gonorrhoea per year (Tapsall JW, 2005) make it an important public health issue. The highest incidence of disease and sequelae occurs prevalently in developing countries. The above approximations are suggested to be underestimated by almost half due to inadequate reporting measures where the disease is concentrated as well as the prevalence of asymptomatic infections (Tapsall JW et al, 2001). Mainly teen-agers and young adults, aged less than 20 or 25 years, are at risk for infection. High-risk groups for gonorrhoea are also commercial sex workers and homosexual active men; moreover, a previous episode of gonorrhoea or a more general history of sexually transmitted diseases (STDs), is also documented to be a risk factor for gonorrhoea infection (Giuliani M et al, 1998).

N. gonorrhoeae is an exclusive human pathogen highly adapted to mucosa tissue, and transmitted by sexual contact. Although the urethra and the uterine cervix serve as the initial sites for gonococcal infection in men and women, respectively, infection of the conjunctiva, pharynx and rectal mucosa are also reported (Edwards JL et al, 2004). In addition, susceptibility to chronic complications associated with *N. gonorrhoeae* infection particularly affect women and, as consequence, their fertility; the newborns, and the risk of acquisition of with Human Immunodeficiency Virus (HIV) in both sexes. In particular, gonococcal infection enhances of five-fold the risk of HIV-1 transmission (Laga M et al, 1993). Gonorrhoea can be effectively treated with antibiotics. However, as with most bacteria under antibiotic pressure, gonococcal antibiotic resistance has recently emerged (CDC annual report, 2003).

In fact, surveillance of antimicrobial resistance in several country showed a progressively increase in resistance over time (Gonococcal Isolate Surveillance Program (USA) [**GISP**], Gonococcal Resistance to Antimicrobials Programme (Canada and United kingdom) [**GRASP**] and Australian Gonococcal Surveillance Program [**AGSP**]). In particular, the emergence and spread of gonococcal resistance to the quinolones in West Pacific Region, but also in Australia and in Nord Europe (Tapsall JW et al, 2005) has been dramatically increased. Also for penicillin, used to treat gonococcal infection since 1980 (Handsfield H et al, 1999), it was observed antimicrobial resistance mediated not only by penicillinase production but also by chromosomal changes in specific genes. Antibiotic resistance in *N. gonorrhoeae* represents an important obstacle to effective treatment and disease control. Increasing antibiotic resistance in *N. gonorrhoeae* as well

as the important health suggest the need of an integrated approach in which provision of effective treatment is essential for the individual patient to interrupt transmission chain and to reduce overall burden. Accurate surveillance data on the distribution of determinants of resistance is also essential for national and international treatment guidelines. In 2002, it was established a European network to identify reference centres for the European Gonococcal Susceptibility Programme (EuroGASP). The Istituto Superiore di Sanità (I.S.S.), at the Department of Infectious Parasitic and Immune-mediated Diseases, is the laboratory of experts for *Neisseria gonorrhoeae* in Italy.

Gonorrhoea rarely kills directly, yet the morbidity and sequelae and/or complications are substantial, although not readily quantifiable in term of human health costs. Nonetheless, some estimates of the benefits of effective treatment have been gathered. One calculation suggests that, for every 100 women treated successfully for gonorrhoea, 25 cases were of pelvic inflammatory disease, 7 cases of *ophtalmia neonatorum*, and 6 instances of infertility will be prevented (Tapsall JW, 2005). Oven and Piot (WHO, 1995) have estimated the cumulative impact of treating successfully gonorrhoea in a core group.

1.1 Epidemiology

Gonorrhoea declined, from a peak during the Second World War, largely due to the advent of penicillin, and then increased during the sixties and early seventies (Danielsson D et al, 1990). This increase was speculated to be caused by a number of different factors such as increasing treatment failures due to the antibiotic resistance, the introduction of oral contraceptives, the liberation of sexual mores and an increasing travel and tourist industry. Gonorrhoea is a continuing threat to public health worldwide, exspecially in developing countries and some lower socio-economic groups in developed countries. Cases of gonorrhoea in Europe have decreased since the early 1980, with the most dramatic decline in 1985 (Giuliani M et al, 1998; Hughes G et al, 1998). This decline in Europe coincides with the establishment of comprensive educational programmes for changes in sexual behaviour due to the concerns for AIDS and HIV (Panchaud C et al, 2000). The disproportionate impact of AIDS related mortality, on high risk population subgroups may have also contributed to this decrease (Chesson HW et al, 2003). Numbers and rates of acute STIs in any European countries have, however, again been increased since the mid 1990s, the trend for Italy is showed in Figure 1. The incidence of gonorrhoea in the country is estimated from statutory notifications and from more detailed reports received from Sexually Transmitted Diseases (STD) Clinics which voluntarily report the cases to the Istituto Superiore di Sanità since 1991. Data from STD clinics and notifications were available at http://www.simi.iss.it. National incidence for the year 2006 was reported to be 0.43 per 100.000 inhabitants (http://www.data.euro.who.int.cisid).

Figure 1. Incidence of gonococcus infections per 100,000 population in Italy; data from CISID and National surveillance database.

1.2 Biology of *Neisseria gonorrhoeae*

The bacterial family of *Neisseriaceae* comprises Gram-negative cocci and rods. The family has four genera: *Neisseria*, *Moraxella*, *Acinetobacter* and *Kingella*. The genus *Neisseria* contains two species primarily pathogenic to humans: *N. gonorrhoeae* and *N. meningitidis* as well as several usually apathogenic commensal species such as *N. lactamica*, *N. cinerea, N. subflava, N. sicca and N. elongata.*

The organisms are aerobic, enhanced by humidity (most of the species). The growth needs carbon dioxide approximately 5%. *Neisseriaceae* are oxidase and catalase producing (with the exception of *N. elongata*), do not produces endospores, do not exhibit flagella for motility and have an optimal growth temperature of 35-37 °C (Knapp JS et al, 1984).

The human is the only natural host for *N. gonorrhoeae*, which survives poorly outside the human body due to its sensitivity to extreme temperatures desiccation, oxidation, toxic substances as fatty acids, as well as to the fastidious nutritional requirements of the organism (Knapp JS et al, 1984). One of the most striking feature of *N. gonorrhoeae* is the marked degree of variation between isolates. The source of this variation lies not only in spontaneous mutation inside the genes, but also in genetic exchange of DNA with other *Neisseria* species.

Strains of *N. gonorrhoeae* are naturally competent for DNA uptake, and can also exchange genetic material by conjugation. The high degree of random recombinant between chromosomal genetic *loci*, probably mediate by transformation, has to be frequent in nature, and this makes *N. gonorrhoeae* an example of pathogenesis with a fully sexual, i. e. panmictic or non-clonal, population structure (Hamilton HL et al, 2006). This causes

genotypic and phenotypic variability, which is important for evasion or adaptation to immune response of the host, and for development of antibiotic resistance spread.

N. gonorrhoeae infects epithelial surfaces in the human genital tract, including urethra, endocervix and fallopian tubes. It also infects conjunctiva, and infection can damage the cornea leading to blindness (Harry TC et al, 2005; MacDonald N et al, 2008).

Rarely, *N. gonorrhoeae* invades the bloodstream, causing disseminated gonococcal infection. To persist in the male urethra and avoid being washed away by the passage of urine, *N. gonorrhoeae* has developed effective methods to adhere to epithelial cells, and can also be found intracellular (Apicella M et al, 1996). During gonococcal infection, PMNs (polymorphonuclear cells) migrate into the urethral lumen and attach to the cells and extracellular matrix present in the surrounding environment. During the extravasation from the blood and attachment to surfaces, PMNs are activated and exhibit increased phagocytosis activity. Most gonococci taken up by the PMNs are killed, but up to 2% can survive due to their resistant to oxidative killing (Shafer WM et al, 1989). The interaction of *N. gonorrhoeae* with PMNs is an important aspect of gonococcal disease that remain unclear. Several studies have suggested *N. gonorrhoeae* survives within PMN (Bouvet JP et al, 1994; Kenney CD et al 2002) and may replicate in PMN phagosomes with time (Prince GA et al, 2005). In fact, prolonged survival of even a low percentage of internalized bacteria might have a crucial role in the outcome of infection. The persistence of gonococci in resident macrophages, which represent a reservoir of infection, could provide a means to overcome host immune response and promote the

infection. *N. gonorrhoeae* replicating within PMNs, represents an attractive model to explain the chain of persistence of the infection and its possible role in transmission.

Successful colonization by gonococcus can result in a broad spectrum of clinical manifestations of the disease that are, in part, determined by either the specific strain initiating the infection and by the anatomical site infected. An example is the male urethra and the upper female genital tract, in which the gonococci interact with epithelial cells, triggers cytokine release and promotes the influx of PMNs.

1.3 Clinical manifestations of gonorrhoea

N. gonorrhoeae is primarily transmitted by direct human-to-human contact between the mucosal membranes of the urogenital tract, anal canal, or the oropharinx epithelium of the mucous membranes of the urethra in males, and the endocervix in females (Figure 2). The incubation period is typically 1-7 days, but can vary greatly, between women and men. In males, the acute urethritis associated with dysuria and urethral discharge may in rare cases be complicated later by urethral stricture, prostatitis and epididymitis that may lead to infertility (Bolan G et al, 1999).

However, even untreated, the symptoms of urethritis usually spontaneously decrease within 3-4 weeks. Asymptomatic infection is estimated to occur in approximately 10-20% of infected men, but this may vary depending on the population studied.

In females, the bacteria mostly cause uncomplicated cervicitis and/or urethritis characterized by vaginal discharge, dysuria and sometimes irregular bleeding. The infections are more often asymptomatic in women (approximately 50%), favouring the progress of the infection involving uterus and fallopian tubes. Complications primary include Pelvic Inflammatory Disease (PID), as endometritis, salpingitis, tubo-ovarian abscesses and subsequently ectopic pregnancies and infertility (Figure 2). In addition. anorectal and/or oropharyngeal gonorrhoea, often asymptomatic, are common among homosexual men, but also among heterosexuals. *N. gonorrhoeae* may also cause conjunctivitis, mostly in neonates, defined as "*ophtalmia neonatorum*" after, exposure to infected secretion of the mother during delivery. Conjunctivitis may, if untreated, result in blindness (Harry

TC et al, 2005; MacDonald N et al, 2008). Disseminated Gonococcal Infection (DGI) may occur in up to 0.5-3% of infected individuals, most often associated with untreated asymptomatic urogenital infection. Moreover, people deficient in late-acting complement factors: C7, C8 and C9 seems to be more likely to develop the DGI. It has been documented 2 DGI cases in Italy. One of the two caused by an imported, multi-drug resistant strain characterized at ISS laboratory and published by Dal Conte et al, 2006 (paper I). Several clinical manifestations of DGI are documented: dermatitis, arthritis, septicaemia, endocarditic and meningitis. The biological basis in HIV transmission, is related to the increased load of HIV in the semen and vaginal fluid in persons with a concurrent gonorrhoea infection (Anzala AJ et al, 2000).

Figure 2. Transmission and outcome of infection with *N. gonorrhoeae*.

1.4 Virulence Factors

Several virulence factors have been identified in gonococcus allowing the bacterium to successfully infect human host.

Many of the most important virulence factors include pili, opacity-associated (Opa) outer membrane proteins and lipo-oligosaccharide (LOS). All of them undergo to phase and/or antigenic variation (Snyder LA et al, 2001). Antigenic variation helps the pathogen, first of all, to evade the human antibody response; secondly to more efficiently bind to the mucosa and encounter phagocytes.

Pili

Pili are flexible filamentous, composed of thousands of pilin (pilE) protein subunits, in association with other pilus associated proteins. Pili extend several μm (Nassif X et al, 1999) in all directions from the surfaces of gonococci. Pili have a wide variety of functions which, in *Neisseria* species, include bacterial aggregation, adhesion, invasion and host cell signalling modulation (Griffiss JM et al, 1999; Merz AJ et al, 1999). Furthermore, pili are though to contribute to gonococcal pathogenesis not only by promoting the initial anchoring to the mucosal surfaces; these surface appendages are also involved at a later stage of the infection during exposure to human monocytes (Knepper B et al, 1997).

Pili play a critical role in the first steps of initial attachment to host cells (Dehio C et al, 2000). The complement regulatory protein, CD46

(membrane cofactor receptor) is a human-specific, transmembrane protein that is expressed by all nucleated cells (Kallstrom H et al, 1997). In human epithelial cell line, (Kallstrom H et al, 2001), CD46 has been demonstrated the receptor for gonococcal pilus. The binding of pili with CD46 is probably mediated by the phase variable adhesin protein PilC located at the tip of the pilus fibre, and/or PilE (major pilus subunit) (Jonsson AB et al, 1994; Rudel T et al, 1995; Nassif X et al, 1999). This interaction results in a rapid cytoplasm calcium flux derived from intracellular calcium stores and, in the host cell cytoskeleton rearrangements. Most strains carry two homologous, but not identical *pilC* genes, pilC1 and pilC2. A knockout of both these genes results in the lack of expression of pili (Jonsson AB et al, 1995). Pili variation in the amino acid sequence of the major subunit pilE, has been demonstrated to influence the adhesive properties towards various types of epithelial cells (Knepper B et al, 1997).

The pili antigenic variation could explain not only the ability of gonococcus to escape the human immune response but also its ability to adhere to different cells in different sites, such as the cervix and the urethra.

Opa proteins

N. gonorrhoeae outer membrane proteins contains a class of proteins called opacity proteins (Opa). The expression of these proteins contributes to colony opacity and to intracellular aggregation (Swanson J, 1978). Opa proteins are integral outer membrane proteins synthesized as precursors containing signals for inner membrane transport. A single gonococcal strain can harbour up to 12 *opa* genes, and Opa protein expression undergoes

phase variation, i.e. expression of each Opa protein can be independently switched to an "on" or "off" state.

Prediction in the secondary structure suggests that mature Opa proteins possess eight membrane-spanning domains arranged as anti-parallel β strands, giving rise to a membrane-embedded β barrel with four extracellular loops (Bhat KS, et al 1992).

Sequence variation between Opa proteins is observed predominantly within the central two loops, that have been termed "hypervariable domain" 1 (HV-1) and 2 (HV-2). Despite variations in amino acid sequence, almost all currently characterized gonococcal Opa proteins can be grouped into two major classes, according to their binding specificity for human surface receptor: Opa_{HS}–type (the term Opa_{HS} denotes heparansulphate-recognising Opa proteins), and the large group of Opa_{CEA}-type (the term Opa_{CEA} comprises all Opa proteins recognising carcinoembryonic antigen CEA).

Pathogenic *Neisseriae* use Opa_{HS} to engage glycosamminoglican side chain of HSPGs to initiate internalization. In addition, to interact with HSPGs Opa_{HS} is also able to bind extracellular matrix (ECM) proteins such as fibronectin and vibronectin (Van putten et al, 1998). This represents an additional bacteria-host-cell contact point and allows invasion into the cell with low HSPG expression level. Upon CEACAM binding, Opa_{CEA}–positive bacteria, can be internalized by professional phagocytes (granulocytes and macrophages) but also epithelial and endothelial cells, Figure 3. CEACAM1 (or CD66a), the broadest tissue expression of all CEACAMs, was also found on B and T cells. Recently, it has been demonstrated that gonococcal stimulation of the ITIM (immune-receptor tyrosine-based inhibition motif)–bearing CEACAM1 expressed on T cells,

arrests the activation and proliferation of these cells in response to cytokines, suggesting that Opa$_{CEA}$-type gonococci are able to modulate T cell response via CEACAM1 (Boulton et al, 2002).

The extensive variation and rapid evolution of the *opa* genes repertoire, as well as sufficient homology between the conserved region of the *opa* genes, has been exploited to provide a high-resolution typing method for short term transmission of gonorrhoea.. *opa*-typing is high discriminatory and identical opa-types is believed to be a good indicator for sexual tracing, or part of a short chain of disease (O'Rourke M et al, 1995; Ward H et al, 2000; Palmer HM et al, 2001).

Figure 3. Schematic diagram of CEACAM-dependent interactions of Opa$_{CEA}$.expressing *Neisseriae* with different human cell types (a). CEACAMs expressed on epithelial cells are clustered by tightly adhering Opa$_{CEA}$-positive bacteria (b). Rearrangements of the actin cytoskeleton are involved in the subsequent internalization (c). Presence of bacteria derived lipooligosaccharide, or bacteria-induced pro-inflammatory cytokines, stimulate the expression of CEACAM1 on endothelial cells, allowing enhanced adhesion of Opa$_{CEA}$-expressing *Neisseriae* and favouring bloodstream widespread (d). In activated T cells, binding of the Opa$_{CEA}$-positive gonococci to CEACAM1 inhibits T-cell proliferation and activation; similarly, interaction with DC (Dendritic cell) inhibits its maturation (e, f). Binding to CEACAMs on PMNs results in opsonin-independent phagocytosis (g) (Gray-Owen SD et al, 2006).

Lipo-oligosaccharide

Lipopolysaccharide (LPS) constitute a family of toxic glycolipids which are integral in the outer membranes of Gram-negative organisms. These molecules are critical for the integrity and functioning of the outer membrane (Gronow S et al, 2001). They are also important surface antigens and are highly immune-stimulatory properties.

LPS molecule generally consists of a highly hydrophobic Lipid A, a covalently attached region, which can be divided into an inner and outer core, and a polymer of a repeating saccharide.

In contrast to the lipopolysaccharide (LPS) that is prevalent among Gram-negative bacteria, the pathogenic *Neisseriae* have within their outer membranes, LOS molecules, which lack the repeating O-antigen sugar that comprises the polysaccharide side chain of LPS (Giardina PC et al, 1999). LOS produced by *N. gonorrhoeae* is one of the major antigenic and immunogenic components of the bacterium. Antibodies against LOS have several important functions in gonococcal infection. LOS also contribute to serum resistance, an important feature especially associated with systemic infection; conversely, serum sensitive strains are often associated to local infections.

The oligosaccharide substitutions of LOS exhibit both inter and intrastrain variability (Apicella MA et al, 1987; Demarco de Hormaeche R, et al 1988). A single *N. gonorrhoeae* strain and even a single gonococcal cell can express several LOS structures at any given time (Apicella MA et al, 1987). Interconversion of LOS oligosaccharides occurs spontaneously, and is dependent upon the presence or absence of available substrates and enzymes

involved in LOS biosynthesis (Burch CL et al, 1997). Some *N. gonorrhoeae* strains can take an activate form of N-acetylneuraminic (sialic) acid from human blood (CMP-N-acetylneuraminic) and covalently attach it to galactose residues on LOS. The spontaneous conversion of oligosaccharide determinants can change the manner in which the gonococcus associates to host tissue and, hence, can potentially change the course of gonococcal disease. Different LOS structures have been shown to correlate with disease symptomatology: *lacto-N*-neotretraose LOS is associated with symptomatic gonococcal infection, while lactosyl LOS is associated with asymptomatic gonococcal infection (Schneider H,). Bacteria with sialylated LOS become serum resistant not only for the presence of the sialic acid, ubiquitous in the host cell, but also because the membrane attack complex (MAC) does not deposit around the altered LOS.

Moreover, LOS oligosaccharide side chain terminate in epitopes that mimic sugar moieties of mammalian glycosphingolipids such as structures on human erythrocyte membrane (Mandrell RE et al, 1988). This form of molecular mimicry not only provides the bacterium a method of immune escape, but also allows the bacterium to use host-derived molecules that, normally associate with the mimicked structure (Harvey H, et al 2001).

Porins

The gonococcal porins are named porin B IA (PorB1A 35KDa) and porin B IB (PorB1B 37KDa) (Gotschlich EC, et al 1987). The native structure of *Neisseria* porins is trimeric, with each porin comprising three single polypeptides. *Neisseria* porins function as pores, essential for bacterial survival and for ions exchange of ions with the surrounding environment. They form aqueous transmembrane channel and the insertion process leads to the formation of a functional channel at low membrane potential (Edwards JL et al, 2004). A unique feature ascribed to gonococcal porin is its ability to translocate into eukaryotic cell membranes, where it forms a voltage-gated channel that is modulated by host cell ATP and GTP (Rudel TH et al, 1996). ATP and GTP regulate gating of the size and ion selectively of pores, causing a transient change in mammalian membrane potential and interference with host cell signalling. This, has been implicated in pathogenesis due to induction of apoptosis of target cells (Muller, et al 1999). Gonococcal porins play an important role in enabling the bacteria to evade complement-mediated killing. The ability of certain gonococcal strains to down-regulate early complement cascade, prior to the C3 deposition, may be partly responsible for milder symptoms seen in individuals infected with such strains. The complement system has an important role in the innate immune system, mediating direct bactericidal killing and bacterial clearance by enhancing opsonic phagocytosis.

Porins, mediate evasion of complement-dependent bactericidal activities by binding factor H, the main fluid-phase regulatory protein of the alternative pathway of complement, or C4, that inactivate C3b and C4b respectively

(Figure 4, a). This binding interfere with the activation, degranulation and phagocytosis of neutrophils. Porins from *N. gonorrhoeae*, as well as previously described LOS, have been shown to influence the development of serum resistance. The gonococcal porin PorB1A is critical in modulating stable serum resistance, which is not mediated by LOS sialylation. Binding of PorB1A to factor H occurs via the surface-exposed region of the 5th loop of porin (Figure 4 a and b) (Ram S et al, 1998). In addition, several gonococcal strains bearing PorB1A can also down regulate the classical complement pathway regulatory protein C4b-binding protein, which appear to interact with the amino-terminal loop of porin. Moreover, certain serum resistant PorB1B strains may also contain C4bp-binding site.

Previous studies have identified an association between PorB1A isolates and higher resistance to bactericidal activities by normal human sera (Van putten JP et al, 1998; Bauer FJ et al, 1999). Furthermore, PorB1A isolates have been associated with invasive disease like DGI, and this may be affected by the fact that PorB1A but not PorB1B also promotes Opa-independent invasion of epithelial cells.

Any individual gonococcal strain expresses only one of two different proteins, the PorB1A or the PorB1B. Rarely, strains expressing both of the proteins occur (Gill M et al, 1994) . The antigenic expression of PorB within a strain is stable; however, diversities among strains constitute serovar classification using monoclonal antibodies as suggested by Sandstrom E et al, 1980; Knapp JS et al, 1984.

Figure 4. Picture showing the role of porin in complement regulation on the surface of *N. gonorrhoeae*. **a)** Regulation of the classical pathway occurs within C4b-bp binds to porin. Factor H bound to porin regulates in alternative pathway. **b)** Schematic representation of PorB1A and PorB1B proteins. Loops 1 and 5 are essential C4b-bp and for factor H, respectively (Massari P et al, 2003).

IgA

The pathogenic *Neisseria* spp. produce extracellular IgA1 proteases, which cleave humoral and secretory IgA1 at the hinge region and it has been implicated as a virulence factor in the pathogenesis of human mucosal infections caused by gonococcus (Kilian M et al, 1996). Cleavage of intact IgA1 (or S-IgA) results in the loss of Fcα-mediated secondary effector functions such as inhibition of adherence (Hajishengallis G et al, 1992) despite the retention of antigen-binding activity by the Fab α fragments (Mansa B et al, 1986). Moreover, it has been hypothesized that Fab α fragments may block the binding to antibodies and thereby inhibits, for istance, complement activation and bacteriolysis (Kilian M et al, 1996).

IgA1 protease secreted by *N. gonorrhoeae* have recently been suggesting to have several effects when the bacterium is present in the sub-epithelium rather than in the lumen or on the mucosal surface. In particular, recent evidences suggest that the lysosome phagosomal protein LAMP-1 is cleaved by IgA1 protease, and that may contribute to intracellular gonococcal survival (Hauck CR et al, 1997).

1.5 Adherence and invasion

The first stage in the infection process is the colonization of a mucosal surface composed of columnar epithelial cells (Figure 5). Some of the surface components of *N. gonorrhoeae* are involved in attachment and invasion of mammalian cells, as previously described (Griffiss JM et al, 1999). *N. gonorrhoeae* first attaches to the cell surface by pili, shortly after initial attachment, the bacteria become more tightly attached to the epithelial surface.

The second stage of binding and the phagocytic uptake, appear to be mediated in part by Opa protein. Opa is not sufficient for tight binding and invasion, but loss of Opa protein is associated with loss of the ability to adhere and invade epithelial cells. These proteins also mediate the binding of *N. gonorrhoeae* each other to form micro colonies by exposed sugars of LOS of another bacterium. Micro colony formation may aid in the initial colonization of the mucosal surface. Opa proteins are also involved in the cytoskeleton rearrangements required for endocytosis after the adhesion (Grassmè H et al, 1996; Grassmè H et al, 1997). In addition porins contribute to the ability of gonococci to survive inside phagocytes. In particular, of inhibition phagosome maturation down regulates immunologically important, opsonin-dependant cell surface receptors (Bjerknes RH et al, 1995). Porins may play a role in preventing the release of reactive oxygen species from PMNs to extracellular milieu which is consistent with the degranulation inhibition attributed to the action of porin (Haines KA et al, 1991).

Figure 5. Colonization of the human host begins at apical surfaces. Pili and Opa are primarily involved in adhesion process. Porins may facilitate the cytoskeleton rearrangements required for actin-mediated entry of gonococcus into target cells. Following internalization, bacteria could either be killed by macrophages, and/or inhibit phagosome maturation, determining host cell damage (www.textbook.bacteriology.net/neisseria.htlm).

1.6 Prevention

The first step of a correct prevention at all STIs is the reduction of contact at risk. Changes in response to the emerging HIV/AIDS pandemic saw dramatic reductions in the incidence of many acute STIs in the late 1980s (Van der Heyden JH et al, 2000; Adler M et al, 2000). However, the progress in HIV/AIDS therapy and the success in the reduction of case fatality rate, decreased in parallel the attention to its prevention.

Because of the important role of the bacterial STDs in HIV transmission, the WHO has concluded strategies to control bacterial STDs (WHO, 1992). It is noteworthy, how potential transmission in STDs, since sexual intercourse provide limited contacts, often display peculiar characteristics. In particular, there are two main aspects to be considered in gonococcal prevention: antimicrobial resistance control and looking for an effective anti-gonococcal vaccine. In fact, as above mentioned in this Thesis, high degree of genotypic variability of *N. gonorrhoeae*, makes this pathogen prompt to genetic changes with implications also in antimicrobial resistance. In this context, multidrug resistant gonococcal strains, represent a focal point for treatment, reduction of spread, and a possible role to acquire other STI infections. Antimicrobial surveillance is important to monitor the change in drugs susceptibility of the bacterium and to suggest changes in therapy protocol.

An effective vaccine to prevent the disease is an important goal. Human trials using partially lised gonococci, purified pilin or purified porin, failed to confer protection upon natural exposure (Sparling PF et al, 1994). These vaccine formulations, although immunogenic, failed to protect likely due to the intrinsic ability of the gonococcus to undergo high-frequency phase and

antigenic variation of surface structures (Meyer TF et al, 1994). It is clear that patients with uncomplicated gonococcal infection develop antibodies, but they are not reactive against gonococcal antigen from a different strain without any immunological memory (Hedges SR et al, 1999). Thus prompted researchers to look for surface antigens with conserved sequences among strains. Two surface- exposed gonococcal proteins: the macrophages infectivity potentiator (Ng-Mip) and the outer membrane protein A (Ng-OmpA) are recently studied in their structure and in their role during gonococcal infection. In particular, Ng-Mip is involved in intracellular survival, during macrophages interaction. Ng-OmpA is an outer membrane protein possibly involved in the adhesion to epithelial cells, as well as in intra-macrophages survival.

Both of those molecules show interesting features as hypothetical candidates for therapeutic and/or prophylactic therapy against gonorrhoea.

Macrophage Infectivity Potentiator

Macrophage Infectivity Potentiators (MIPs) are surface-exposed or secreted proteins already described as virulence factors in different pathogens such as *Legionella pneumophila* (*Lp*), *Chlamydia trachomatis* (*Ct*), *Trypanosoma cruzi* (*Tc*), and *Escherichia coli* (*Ec*) (Kohler R et al, 2003). These proteins exhibit peptidyl-prolyl *cis/trans* isomerise (PPI-ase) activity, and catalyses the slow *cis/trans* isomerization of prolyl peptide bonds in oligopeptides involved in the proline mediated folding of proteins (Fisher et al, 1992). MIPs belong to the enzyme family of FK506-binding protein (FKBP) (Fischer G et al, 1992; Fischer G et al, 1984; Schmid F et al, 1993) inhibited by T cells immune-modulatory cyclosporines. In particular, FK506 and rapamycin, which are important immunosuppressant are used to treat transplant recipients (Fanghanel J et al, 2004). The addition of PPI-ase inhibitors to *Ct* and *Lp* resulted in reduced infectivity of these organisms suggesting that the inhibition of PPIase activity interferes with the biology of the infection, confirming the role of PPI-ase in bacterial virulence (Lundemose AG et al, 1993; Moro A et al, 1995).

It has been described the identification and characterization of a Ng-MIP in *N. gonorrhoeae*, showing high homology to MIPs proteins (Leuzzi R et al, 2005).

Ng-MIP is a basic 29 KDa protein and the presence of a $L_{18}XXC_{21}$ motif at the putative site cleavage, suggests that the mature polypeptide could be a lipoprotein anchored to the outer membrane through Cysteine at amino acid position 21. Ng-MIP also contains a putative dimerization domain at the N-terminal, supporting the hypothesis that it could exist as a dimer. The C-

terminal of Ng-MIP has high degree of homology with the PPI-ase domain of Lg-MIP and Tc-MIP, suggesting that it could also showed a PPI-ase activity.

Gonococci mutant strains, generated by deletion of *mip* gene (*Δmip*), have the same ability as the wild type, to adhere and to be internalized in macrophages, but have a reduced survival after the infection due to the macrophage killing (Leuzzi R et al, 2005). Therefore, Ng-MIP seems to be important for survival of *N. gonorrhoeae* inside macrophages, highlighting a possible role in promoting the persistence of gonococcal infection. Ng-MIP is specific for macrophages since it does not influence the invasion and the survival of gonococcus in other cells, such as the epithelial cells. Currently, little is known regarding the role of Ng-MIP interaction with phagocytic cells as well as its PPI-ase activity in *N. gonorrhoeae*.

The structure of FK506 complex of Ng-Mip provides a starting point for the design of more specific inhibitors lacking the immune-suppressant property of the molecule. Such inhibitors could be of prime interest for developing new therapies against gonococcal infection.

Outer Membrane protein A

Outer Membrane Protein A (OmpA) is an abundant structural protein of the outer membrane of Gram negative bacteria (Sonntag et al, 1978). It assembles in the outer membrane via an N-terminal eight transmembrane amphipatic β-barrel region with the C-terminal region retained in the periplasm (Koebnik R et al, 2000; Pautsch A et al, 1998). Unlike other surface-exposed of the bacterial cell envelope, OmpA is highly conserved among the *Enterobacteriaceae* and throughout the evolution (Poolman JT, et al 1996). OmpA functions include first of all the maintenance of structural membrane integrity during the invasion into mammalian cells (Weiser JN et al, 1991). OmpA-deficient in *E. coli* exhibit attenuated virulence invasive capacity and resistance to serum bactericidal activity (Weiser JN, et al 1991). In particular, OmpA contributes to serum resistance by binding to the complement regulatory protein C4bp (Prasadarao NV et al, 2002) leading to a decrease in serum killing, a mechanism used by many pathogens to avoid complement attack.

Interestingly, in contrast to most of the soluble foreign proteins that produce a weak immune response or tolerance, when administered in the absence of an adjuvant, OmpA from different species induces specific humoral (Poolman JT, 1996) and cytotoxic responses (Kim SK et al, 2000) also in the absence of adjuvant. In particular, it has been demonstrated that the recombinant 40 KDa OmpA from *Klebsiella pneumoniae*, interacts with human immune cells and particularly with antigen presenting cells (APCs) via endocytic receptors on host cell surfaces (Jeannin P et al, 2002). This property contributes to explain its unusual immunogenicity driving interest

for future vaccine strategies as target for antigen delivery and for cytotoxic T-lymphocytes (CTLs) induction.

Serino L. and colleagues, have recently described a gonococcal OmpA-like protein, defined as Ng-OmpA, playing a significant role in the entry and in the intracellular survival in macrophages. In particular, the knockout mutant (*ΔOmpA*), demonstrated reduced recovery in a mouse model of infection when compared with the wild type strain, suggesting that Ng-OmpA play an important role in *in vivo* colonization by *N. gonorrhoeae*. Ng-OmpA is a surface-exposed lipoprotein with a predicted molecular mass of 23 KDa, showing a significant homology with the OmpA expressed by several microrganisms such as *Escherichia coli*, and *Salmonella typhimurium* (Serino L et al, 2007). Currently, little is known regarding Ng-OmpA and its exact function and role in the pathogenesis of gonorrhoea. However, studies regarding OmpA features, as possible candidate vaccine, further investigations will be performed.

1.7 Aims

Data regarding the trend and the group at risk for *N. gonorrhoeae* infection originates mainly from North Europe and United States. Few publications exist from Central and South Europe, including Italy concerning the epidemiology and microbiological characteristics of circulating strains.

From April 2003 to December 2007, a study on clinical and microbiological characteristics of the isolates was undertaken.

The aims of the present Thesis were:

- to investigate the phenotypic and genotypic features of isolates. In particular, the antimicrobial susceptibility and the analysis of the molecular changes responsible for antibiotic resistance.

- to analyse the genetic relatedness among gonococcal strains circulating in the study period in Italy.

- to analyse the *mip* and *ompA* gene sequences, as well as their gene products, to investigate gene conservation among a selected group of isolates showing different phenotypic and genotypic characteristics associated with different clinical pictures.

- to evaluate the recognition, by human sera collected from infected patients, of purified Ng-Mip and Ng-OmpA proteins.

- to evaluate the role of Ng-Mip and Ng-OmpA in the serum bactericidal activity using *N. gonorrhoeae* knockout strains for the two genes.

2. Materials & Methods

2.1 Samples collection

 N. gonorrhoeae clinical isolates were accompanied by a patient questionnaire with epidemiologic information about nationality, residence, sexual orientation, previous antibiotic use, number of sexual partners, as well as clinical information (sex, age, diagnosis, HIV infection and immune status compromising). Sera samples, acute and convalescent, when available, were obtained from patients at approximately two-weeks of interval. Those sera were sent to I.S.S., for serological studies and for storage at -80°C.

2.2 Bacterial strains and phenotypic analysis

A total of 729 cases were investigated during the study period. In particular, 583 *N. gonorrhoeae* isolates were stored in BHI (Brain Hearth Infusion) broth with 20% glycerol at -80°C.

The isolates were cultured as purified colonies on Thayer Martin medium with 2% IsoVitaleX (Oxoid LTD, UK) at 37°C in 5% CO_2. Knockout F62 *N. gonorrhoeae*: Δ*mip* and Δ*ompA*, strains were cultured on Thayer Martin medium added with 1% IsoVitaleX (Oxoid LTD, UK) and 5 mg/ml of erythromycin (Sigma Aldrich, USA).

2.2.1 Serotyping

Serological group (serotyping) of all isolates was obtained with Phadebact GC serovar test (Boule Diagnostics, Sweden) by a co-agglutination using monoclonal antibodies directed against PorB1A and PorB1B proteins encoded by the mutually exclusive alleles of the *porB* gene, *porB1A* and *porB1B*, respectively (Knapp JS et al, 1984; and Sandstrom E et al, 1980). Bacterial suspension in sterile Phosphate Buffered Saline (PBS) was used to react with the monoclonal antibodies. The strains with cross-reactivity (IA/IB) were re-tested to confirm the result.

2.2.2 Antimicrobial susceptibility analysis

The antimicrobial susceptibility test for: ciprofloxacin, penicillin, tetracycline, azithromycin, spectinomycin and ceftriaxone was determined by the E-test (AB Biodisk, Sweden) following the manufacturer's instructions. Strains were plated onto Thayer Martin (TM) plates supplemented with 2% IsoVitaleX (Oxoid, Ltd UK) cultured over night (o. n.). After 24h of growth, gonococcal cell suspensions, prepared in sterile PBS, up to a density of 0.5 McFarland, were plated on TM agar supplemented with 1% IsoVitaleX at 37°C and 5% CO_2. Minimum Inhibitory Concentration (MIC) breakpoints for each antimicrobial agent are shown in Table 1.

For tetracycline, to confirm the MIC close to breakpoint, the agar dilution method was also included. Penicillinase production was determined using the chromogenic nitrocefin test (Oxoid, Ltd UK).

 N. gonorrhoeae reference strain ATCC 49226 was includes in each test, as control.

Table1. Breakpoints as defined by NCCLS (CSLI), 2006.

Antimicrobial agent	Susceptible (mg/L)	Intermediate (mg/L)	Resistant (mg/L)
Penicillin	≤0.06	0.12-1	≥2
Tetracycline	≤0.25	0.5-1	≥2
Ciprofloxacin	≤0.06	0.12-0.5	≥1
Spectinomycin	≤32	64	≥128
Ceftriaxone	≤0.25	-	-
[a]Azithromycin	-	-	≥1

[a] Azithromycin breakpoint was that from the Centre for Disease Control and Prevention (2003) *Neisseria gonorrhoeae* reference strains for Antimicrobial Susceptibility, B88, August 2005.

2.3 Molecular analyses

2.3.1 DNA preparation, PCR amplification and DNA sequencing

Chromosomal DNA used as template was prepared with QIAamp DNA minikit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. Plasmid DNA was prepared by boiling a bacterial suspension in PBS after 24 h of growth.

Amplification reactions were carried out as previously described for each target gene and oligonucleotides are listed in Table 2. All purified PCR products (QIAquick PCR purification Kit, QIAGEN) were subjected to automated sequencing. Sequences analyses were performed with Chromas version 6 software, and BLAST website program (http://www.ncbi.nlm.nih.gov/BLAST) was used to compare the sequences with those available on the website.

Table 2. Primers used for PCR amplification and sequencing to study antimicrobial resistance.

Antimicrobial agent	Targets involved in resistance		Primer sequences (5'→3')
Penicillin	Plasmid PPNG[a]	*B-lactamase* (Toronto-Rio/ African plasmid)	**BL1** (forward) [1545]TACTCAATCGGTAATTGGCT[1564] **BL2** (forward) [3606]CACCTATAAATCTCGCAAGC[3625] **BL3** (reverse) [4564]CCATAGTGTTGAGTATTGCGAA[4585] **BL4** (reverse) [6528]TCATTCGTGCGTTCTAGGA[6546]
Ciprofloxacin	Chromosomal QRNG[b]	*gyrA*	**gyrA1** (forward) [160]CGGCGCGTACTGTACGCGATGCA[182] **gyrA1X** (reverse) [438]AATGTCTGCCAGCATTTCATGTGAGA[413]
		parC	**parC1** (forward) [166]ATGCGCGATATGGGTTTGAC[185] **parC2X** reverse [20]CGACAACAGCAATTCCGCAA[401]
Tetracycline	Chromosomal CMRNG[c]	*rpsJ*	**rpsJ1** (forward) [23]TCCGCCTGAAAGCTTATGAT[42] **rpsJ2** (reverse) [246]TTATCGGTCCAATCCACGAT[227]
	Plasmid TRNG[d]	*TetM*[e] (American /Dutch type plasmid)	**UF** (forward) [825]CTCGAACAAGAGGA[842] **AR** (reverse) [1602]GCATTCCACTTCCCAAC[1586] **DR** (reverse) [1267]TGCAGCAGAGGGAGG[1253]

[a] Penicillinase-producing *N. gonorrhoeae*

[b] Quinolone-resistant *N. gonorrhoeae*

[c] Chromosomally-mediated resistance *N. gonorrhoeae*

[d] Tetracycline resistant *N. gonorrhoeae*

[e] The primer sequences derived from the sequences of *TetM* pOZ100 (UF, AR) and *TetM* pOZ100 (AR) which accession number were L12241 and L12242.

Numbering is referred to *N. gonorrhoeae* strain MS11 (accession number M21289).

2.4 Genotypic analyses

For genotypic analysis the gonococcal strains were typed by PCR-Restriction Fragment Length Pattern (RFLP) of *opa* genes, Pulsed-Field Gel Electrophoresis (PFGE) and *N. gonorrhoeae* Multi-antigen Sequence Typing (NG-MAST).

2.4.1 PCR-RFLP of *opa* genes

Typing of *opa* genes was performed on a subset of samples, 128, and based on method previously described by O' Rourke et al, 1985. The 11 *opa* genes were amplified with a single pair of primers (opa-up [663]GCG ATT ATT TCA GAA ACA TCC G [687] and opa-down [1227]GCT TCG TGG GTT TTG AAG CG [1207]) and digested with 40 U of *Taq*I (New England, BioLabs) for 2 h. Gonococcal yielding identical restriction fragment patterns were considered to have the same Opa-Type (OT). Isolates differing by even a single fragment were assigned to different OTs. Isolates that gave identical patterns with *Taq*I, were then digested with 40 U of *Hpa*II (New England, BioLabs) restriction enzyme for 2 h (Van M et al, 1999) in order to confirm the result.

2.4.2 Pulsed-Field Gel Electrophoresis

Bacteria were suspended in sterile PBS to a final concentration of 4 McFarland. From each suspension 200 μl were used for preparation and digestion of bacterial DNA. The suspension after centrifugation were resuspended in lysis buffer (EC+RNA-asi 50μg/ml+Lisozima 1mg/ml) and mixed to an equal volume of 1.2% (wt/vol) low melting preparative-grade agarose (Bio-Rad, Laboratories) and dispensed into plastic plugs. The

solidified plugs were incubated o. n. at 37° C with 40U of *Spe*I (New England, Biolabs) (Mavroidi A et al, 2001) and 30 U of *Nhe*I (New England, Biolabs). The slides of agarose containing the chromosomal DNA fragments were inserted into the wells of 1% agarose gel (Bio-Rad) and the electrophoresis was performed in CHEF-Mapper II apparatus (Bio-Rad, Hercules, CA). The run comprised the following parameters: 0.5s and 54s of ramping time and a running time of 21h at 6V/cm in a 0.5X TBE buffer (45 mM Tris-borate, 45 mM Tris base, 45 mM boric acid and 1 mM EDTA). The Lambda ladder PFG marker (New England, Biolabs) was used as molecular size standard. The reference *N. gonorrhoeae* strain FA1090 was included in each run. The gels were stained with 2mg/ml ethidium bromide destained in double distilled water, photographed under UV lights and digitized with Gel Doc 2000 system apparatus (Bio-Rad, CA).

DNA restriction patterns were compared to determine their relatedness. Strains with patterns varying by three or less fragments were considered as the same PFGE type (Tenover FC et al, 1997; Goering RV et al, 1993). The PFGE banding patterns were analyzed with the Diversity Database Fingerprinting Software (version 2, Bio-Rad Laboratory).

2.4.3 *N. gonorrhoeae* Multi-antigen Sequence Typing

Amplification of *por* and *tbpB* genes was performed on a total of 175 gonococci chosen among sensitive and resistant to drugs. PCR parameters were those suggested by Martin I et al, 2004.

Oligonucleotides were those listed in Table 3.

Primers for *por* gene were designed on conserved regions encoding the pre-loop 2 and pre-loop 8 of the protein, in order to amplify both classes of alleles (*por* IA and *por* IB respectively). After being sequenced selected fragments, for *por* and *tbpB* gene, respectively were entered into a publicly accessible database on the NG-MAST website: www.ng-mast.net, in order to define the corresponding alleles and the resulting Sequence Type (ST).

Table 3. Primers used for amplification and sequencing of *por* and *tbpB* alleles for NG-MAST typing.

Primers	Nucleotide position[a]
por forward	[350] CAA GAA GAC CTC GGC AA [366]
por reverse	[1086] CCG ACA ACC ACT TGG T[1070]
tbpB forward	[1098] CGT TGT CGG CAG CGC GAA AAC [1119]
tbpB reverse	[1686] TTC ATC GGT GCG CTC GCC TTG [1665]

[a] Numbering is based on *por* and t*bpB* sequences of *N.gonorrhoeae* MS11strain (accession number M21289).

2.5 Ng-*mip* and Ng-*ompA* gene sequence analyses

The entire *mip* and *ompA* genes were amplified from 20 *N. gonorrhoeae* clinical isolates. The primers used for PCR reactions are showed in Table 4. Amplifications parameters were: 15 min at 95°C, followed by 35 cycles of which 1 min of denaturation at 95°C, 1 min of annealing at 55°C or 60°C for *mip* and *ompA* genes, respectively, 1 min of elongation at 72°C. Purified PCR products (QIAquick PCR purification Kit, QIAGEN), were subjected to automatic sequencing. Nucleotide and amino acid sequences were analyzed with Chromas software version number 6 and with BLAST website (http://www.ncbi.nlm.nih.gov/BLAST). Multiple sequence alignments were performed with DNA*Man* software version 5.2.10 (Lynnon BioSoft, Canada).

Table 4. Primers used for PCR amplification and sequencing of *mip* and *ompA* genes.

Primers	Nucleotide position[a]
*mip*1 forward	[816]AAC ACC ATT TTC AAA ATC AG [798]
*mip*2 reverse	[1]TTA ATT TAC TTT TTT GAT GTC G [22]
ompA forward	[1]ATGACTTCTTCAAACCCTC [20]
ompA reverse	[678]TTA CAT GTG CCG TGC GGC [661]

[a]Numbering is based on *mip* and *ompA* gene sequences of *N. gonorrhoeae* FA1090 (accession number AE004969).

2.6 Western blot analysis

Western blot analysis was performed according to standard procedures (Laemmli UK, 1970). Recombinant Ng-OmpA or Ng-MIP (kindly provided from Novartis, Italy), were run on 12% acrylamide at a 100V for 1h. After blotting the nitrocellulose membranes, were incubated for 2 h at room temperature (r. t.) with sera from gonorrhoea infected patients, then washed twice with saline buffer added with 0.05% of Tween 20. Then, were incubated for 1 h at r. t. with antihuman IgG antiserum (Fc-specific)-Alkaline Phosphatase (Sigma Aldrich, USA). Peroxidase substrate (SIGMA FAST BCIP/NBT Sigma Aldrich) was used for the detection reaction. Molecular weight standard (New England, Biolabs) was included in each gel. Polyclonal mouse antiserum, raised against recombinant Ng-Mip and Ng-OmpA proteins, respectively, were used as positive controls.

2.7 Serum bactericidal activity

A total of six sera samples from patients infected with gonorrhoea were used, after heat inactivation (at 56°C for 30 min), in the serum bactericidal activity. These sera samples were separately tested against 6 *N. gonorrhoeae* strains, as well as, *Δmip* and *ΔompA* knockout strains. Gonococcal strains after 24 h of growth were suspended in GC broth supplemented with 1% IsoVitaleX (Oxoid, Ltd UK) up to an optical density of 0.2. The broth culture was monitored until it reached 0.4 OD (mid-log growth phase). Aliquots of 12.5 µl of the cell suspensions (containing about 100 colony forming unit), were added to 25 µl of the heat-inactivated serum sample (serially diluted), and 12.5 µl of baby rabbit serum, as complement source . The final volume of all reaction mixtures was 50 µl. The microplate was then incubated at 37°C in 5% CO_2 for 1 h. Ten microliter aliquots of the reaction mixtures were plated onto GC agar at time 0 and after 60 min. Percentage of survival was expressed as the percentage of colonies on a plate at 60 min compared with those on the plate at 0 min.

3. Results

3.1 Characteristics of the study population

From April 2003 to December 2007 a total of 729 cases of gonorrhoea were recorded in our database. As shown in Table 5, considering the range of different ages among males and females infected, it was noteworthy that most of the infections occurring among males, 18-67 year age range; while for females it was 17-41. More than 60% of infected patients were among heterosexuals. Since the cases were predominantly among male, the male urethra was the most frequent site of isolation with discharge/dysuria the main associates symptoms.

Interestingly, it has been recorded 3 cases of disseminated gonococcal infections.

A mean of 10.3% of patients with gonorrhoea were also HIV-1 positive.

Table 5. Clinical data of patients infected with *N. gonorrhoeae* strains isolated in Italy during the study period.

N° of cases	Mean age (range)	Sex (%)	Nationality (%)	Sexual orientation (%)	HIV infection (%)	Site of specimen (%)
729	M[a] 33 [18-67]	M (91.3)	Italian (79.7)	Heterosexual (62.2)	Positive (10.3)	Urethra (87.7)
	F[b] 23 [17-41]	F (7.9)	European (15.7)	Homosexual/ Bisexual (37.8)	Negative (89.1)	Cervix (8.1)
			Others (4.6)		Unknown (0.6)	Other (4.2)

[a] M: Male.
[b] F: Female.

3.2 Phenotypic analyses

Serotyping was performed on a total of 481 isolates. Most of the gonococci isolated were serotype IB (90.1%), the remaining were serotype IA/IB and IA, 7.2% and 2.7%, respectively. Those strains showing a cross-reactive serotype, IA/IB, were re-tested in order to confirm the result.

As showed in Table 6, gonococci resistant to ciprofloxacin, penicillin, and tetracycline were recorded in the study.

Ciprofloxacin resistant strains (QRNG) were 46% of all gonococci analysed. Few strains showed reduced susceptibility to ciprofloxacin (Table 6).

Penicillin resistance was observed in 20% of the analysed strains (Table 6). Most of the isolates (97%) were PPNG (i.e. carrying African type or Toronto/Rio, β-lactamase-producing plasmid). The remaining 3 % were CMRNG, with a negative β-lactamase nitrocefin test.

Tetracycline resistant gonococci were 28.3% of the total. The 44.6% showed a TRNG phenotype (carrying plasmid with *TetM* determinant, American or Dutch type); the 23% were CMRNG. Noteworthy, 32.4% of tetracycline resistant gonococci showed both the TRNG/CMRNG phenotypes.

Interestingly, more than 40% were strains with reduced susceptibility to penicillin or tetracycline Table 6.

Antimicrobial susceptibility analysis for azithromycin was performed on a total of 172 gonococci out of 481, the 11.6 % of them were resistant (Table 6).

All the isolates were susceptible to spectinomycin and ceftriaxone.

Multidrug resistant strains were also found in this study. Twenty-four percent and 4.4% resulted resistant to 2 or 3 antibiotics, respectively. Resistance to ciprofloxacin plus tetracycline was the most frequently combination found (17.3%).

Table 6. Percentages of susceptible, intermediate and resistant *N. gonorrhoeae* strains by antimicrobial agents.

Antimicrobial agent	N° of isolates	S (%)	I (%)	R (%)
Ciprofloxacin	481	45.7	4	46
Penicillin	481	19.1	49.4	20.4
Tetracycline	481	22.2	42	28.3
Azithromycin	172	-	-	11.6

[a]S: Susceptible

[b]I: Intermediate

[c]R: Resistant

3.3 Molecular analyses

Resistance to ciprofloxacin was conferred by amino acid changes in *gyrA* and *parC* genes. In particular, sequence analyses were performed on a total of 94 out of 129 ciprofloxacin resistant strains. The results revealing the following amino acid substitutions: $S_{91}\rightarrow F$, $D_{95}\rightarrow G/A/N$ in *gyrA* gene, $S_{87}\rightarrow I/R/N$, $D_{86}\rightarrow N/H$, $E_{91}\rightarrow K$ in *parC* gene. However, the most frequent pattern mutations was: $S_{91}\rightarrow F$, $D_{95}\rightarrow N$ in *gyrA* gene and $D_{86}\rightarrow N$ in *parC* gene with a MIC range was 8-32 mg/L.

All but one ciprofloxacin resistant strains, showed at least one amino acid substitution in both of the gene. The exception showed an amino acid substitution only in the *parC* gene. This was associated with a lower MIC value for ciprofloxacin, 6 mg/L.

Penicillin resistance was prevalently associated to β-lactamase producing plasmid: Toronto/Rio (61%), and African type plasmid 39%. Chromosomally mediated penicillin resistance was 3%.

Resistance to tetracycline was conferring either by plasmid carrying *TetM* determinant (TRNG) or by point mutation in *rpsJ* with the gene amino acid substitution $Val_{57}\rightarrow Met$ (CMRNG). In particular, among TRNG isolates, the American type plasmid was the most frequent. The co-existence of both the plasmid and chromosomally mediated resistance (TRNG/CMRNG) was identified in 32.4% of the gonococci analysed.

3.3.1 Genotypic analyses

A representative number (40%) of resistant and susceptible isolates was typed by molecular methods including *opa*-typing, NG-MAST, and PFGE analysis.

Opa-type profiles are shown in Figure 6**.** In particular, *opa*-type 1 was the most frequent (66.4 %) identified among the antimicrobials resistant strains examined. Most of the gonococci resistant to ciprofloxacin, penicillin or to both of these two drugs, showed *opa*-type 1. However among 7 *opa*-type profile identified, *opa*-type 1 to 6 (Figure 6, lanes 1 and 6) were recovered in ciprofloxacin resistant strains while *opa*-type 1, 2. 3, 5 and 7 were prevalent in penicillin resistant strains.

NG-MAST analysis performed on a total of 175 strains. A total of 66 STs were identified, comprising both novel and previously described STs (Figure 7). Among 62 STs observed 39 occurred only once (singletons), most of them associated exclusively with homosexual transmission. The remaining 23 were clusters of two, three and four isolates. Interestingly, it has been identified the presence of a large cluster of isolates showing sequence type ST661, most of which were *opa*-type 1. The transmission of ST661 was associated with heterosexual behaviour. All the isolates identified as ST661 were serogroup IB and were resistant to penicillin, ciprofloxacin and resistant or had reduced susceptibility to tetracycline. The percentage of ST661 isolates resistant to one, two or three drugs was 3.7%, 83.3% and 13%, respectively. In particular, ST661 clone was circulating in Italy in Turin province. Its circulation in this geographic area peaked from October to December 2003. The isolation rate decreased and the appearance of 3 other STs was seen. These 3 STs: ST657, ST1252, and ST1253, which

were exclusively found in Turin, shared the same *tbpB* allele with ST661 but have different *por* allele. However, two of the STs (ST657 and ST1252) each different from ST661 by a non-synonymous point mutation in the *por* gene fragment and would therefore be considered to be part of the same cluster. ST657 and ST1252 profile analysis were identical and closely related to that of ST661, respectively. Conversely, ST1253 had an unrelated profile to strains ST661, ST657 and ST1252. This is consistent with the relatedness by the NG-MAST result described.

PFGE analysis performed on a total of 76 strains. In particular, those strains representing the same *opa*-type, showed also the same PFGE pattern profile (Figure 8, lane 1) confirming the presence of a clone.

PFGE analysis showed identical profiles among the strains belonging to ST661 and ST657 (Figure 8, lane 1 and 2) and a closely related profile for strains of ST1252 (Figure 8, lane 3). ST1253 had an unrelated profile to strains of ST661, ST657 and ST1252 (Figure 8, lane 4).

Figure 6. Examples of *opa*-type identified in the study. Lane MW, pBR322 *Msp*I digest molecular DNA marker (New England , Biolabs). Lanes 1-7, *opa*-type from 1 to 7, respectively.

Figure 7. Pie chart depicting different *N. gonorrhoeae* Sequence Types (STs) identified among the Italian isolates examined. ST661 represents the largest cluster of isolates identified. ST singletons* include the total number of the STs represented by only one isolate; indicates STs that are not previously identified. The remaining STs are clusters of two, three or four isolates.

Figure 8. PFGE patterns of *Spe*I-digested genomic DNA from *N. gonorrhoeae* isolates belonging to STs: ST661, ST657, ST1252 and ST1253 (lane 1-4). MW: Molecular weight marker (New England, Biolabs).

3.4 Sequence analyses of *mip* and *ompA* genes and their gene products

To investigate *mip* and *ompA* genes conservation PCR amplification and sequences analyses were performed on selected strains representing the STs most frequently found in the country. In particular, gonococci were chosen to represent different clinical and microbiological characteristics (Table 7). Comparison of *mip* gene sequences of 20 *N. gonorrhoeae* clinical isolates, and F62 strain, revealed a high degree of gene conservation. However, deduced amino acid sequences revealed the presence of 2 amino acid substitutions, $S_{59} \rightarrow G$ and $E_{160} \rightarrow K$, compared with *N. gonorrhoeae* FA1090 (Figure 9). Most of the isolates showed the presence of both these substitutions. Six strains showed only the presence of. $S_{59} \rightarrow G$ localized in the N-terminal region of the gene (Figure 8). $E_{160} \rightarrow K$ substitution was localized in the C-terminal region, involved in the catalytic activity of the protein (PPI-ase activity). In particular, the latter did not alter the biological activity of the protein. An hypothetical Ng-Mip protein structure, obtained with software SwissPdb Viewer (http://www.expasy.org/spdbe/), is shown in Figure 10.

OmpA gene sequences as well as their deduced amino acid sequences were completely identical either among the clinical isolates tested, the F62, and the FA1090 strain.

Table 7. Microbiological features of strains selected for *ompA* and *mip* gene sequence analysis

Year of isolation	Serotype	MIC TC[a] (mg/L)	MIC PG[b] (mg/L)	MIC CI[c] (mg/L)	Sequence Type by NG-MAST
2003	IB	1	32	6	ST 661
2003	IB	0.5	32	6	ST 661
2003	IB	1	32	1	ST 661
2003	IB	2	32	32	ST 661
2003	IB	1	32	8	ST 661
2003	IB	1	32	6	ST 661
2004	IA/IB	24	32	4	ST 147
2004	IB	16	32	8	ST 1253
2005	IA/IB	0.25	0.032	0.08	ST 1242
2005	IB	0.38	1.5	32	ST 225
2007	IA/IB	2	0.5	32	ST 954
2007	IB	2	32	32	ST 225
2007	IB	16	0.094	0.003	ST 1954
2007	IB	2	0.5	32	ST 935
2007	IB	2	0.38	12	ST 663
2007	IB	2	0.38	32	ST 935
2007	IB	0.25	0.016	0.004	ST 660
2007	IB	1	0.38	32	ST 69
2007	IB	2	1	32	ST 1241
2007	IB	1	0.125	0.004	ST 4

[a] TC: Tetracicline.
[b] PG: Penicillin.
[c] CI: Ciprofloxacin.

```
G617-mip    -MNTIFKISA LTLSAALALS ACGKKEAAPA SASEPAAASA AQGDTSSIGG
G627-mip    -MNTIFKISA LTLSAALALS ACGKKEAAPA SASEPAAASA AQGDTSSIGG
FA1090-mip  -MNTIFKISA LTLSAALALS ACGKKEAAPA SASEPAAASA AQGDTSSIGS
F62-mip     -MNTIFKISA LTLSAALALS ACGKKEAAPA SASEPAAASA AQGDTSSIGG


G617-mip    TMQQASYAMG VDIGRSLKQM KEQGAEIDLK VFTDAMQAVY DGKEIKMTEE
G627-mip    TMQQASYAMG VDIGRSLKQM KEQGAEIDLK VFTDAMQAVY DGKEIKMTEE
FA1090-mip  TMQQASYAMG VDIGRSLKQM KEQGAEIDLK VFTDAMQAVY DGKEIKMTEE
F62-mip     TMQQASYAMG VDIGRSLKQM KEQGAEIDLK VFTDAMQAVY DGKEIKMTEE


G617-mip    QAQEVMMKFL QEQQAKAVEK HKADAKANKE KGEAFLKENA AKDGVKTTAS
G627-mip    QAQEVMMKFL QEQQAKAVEK HKADAKANKE KGEAFLKENA AKDGVKTTAS
FA1090-mip  QAQEVMMKFL QEQQAKAVEK HKADAKANKE KGEAFLKENA AKDGVKTTAS
F62-mip     QAQEVMMKFL QEQQAKAVEK HKADAKANKE KGEAFLKENA AKDGVKTTAS
            160
G617-mip    GLQYKITKQG EGKQPTKDDI VTVEYEGRLI DGTVFDSSKA NGGPATFPLS
G627-mip    GLQYKITKQG KGKQPTKDDI VTVEYEGRLI DGTVFDSSKA NGGPATFPLS
FA1090-mip  GLQYKITKQG EGKQPTKDDI VTVEYEGRLI DGTVFDSSKA NGGPATFPLS
F62-mip     GLQYKITKQG KGKQPTKDDI VTVEYEGRLI DGTVFDSSKA NGGPATFPLS


G617-mip    QVIPGWTEGV RLLKEGGEAT FYIPSNLAYR EQGAGEKIGP NATLVFDVKL
G627-mip    QVIPGWTEGV RLLKEGGEAT FYIPSNLAYR EQGAGEKIGP NATLVFDVKL
FA1090-mip  QVIPGWTEGV RLLKEGGEAT FYIPSNLAYR EQGAGEKIGP NATLVFDVKL
F62-mip     QVIPGWTEGV RLLKEGGEAT FYIPSNLAYR EQGAGEKIGP NATLVFDVKL


G617-mip    VKIGAPENAP AKQRY
G627-mip    VKIGAPENAP AKQRY
FA1090-mip  VKIGAPENAP AKQ--
F62-mip     VKIGAPENAP AKQRY
```

Figure 9. Alignment of Ng-Mip amino acid sequences. G617 and G627: clinical isolates. Sequence of FA1090 *N. gonorrhoeae* strain was derived from the NCBI database available at accession number AE004969.
Amino-acid substitutions in Ng-Mip protein and their positions are indicated in bold.
Ng-Mip dimerization domain, localized at N-terminal region, are underlined; PPI-ase domains, localized at C-terminal region, are highlighted in yellow.

**Figure 10.** Ng-Mip structure with the secondary structure elements α-helices and β-strands. The side chains of residues interacting between the two monomers (violet and orange), are depicted as ball-and-stick models (SwissPdb, Viewer http:// www.expasy.org/spdbe/).

3.4 Western blot analysis

A total of 12 sera samples, collected from patients with gonorrhoea, were tested in western blot assay to evaluate the presence of antibodies against Ng-Mip and Ng-OmpA recombinant proteins, respectively. Some of the tested sera were collected from patients whose strains was previously analysed by sequencing the *mip* and *ompA* genes.

Ng-Mip and Ng-OmpA proteins migrate at an approximately molecular mass of 28 and 23 KDa, respectively. The samples recognized both of the proteins (Figure 11). Interestingly, also the serum sample from a patient with DGI was able to react with the proteins (Figure 11).

Figure 11. Western blot analysis of sera samples from patients with *N. gonorrhoeae* infection. Ng-Mip and Ng-OmpA recombinant proteins were run on a 7-12% SDS-PAGE, and the proteins were transferred on nitrocellulose membranes. The blots containing both of the proteins, were separately probed with non-immune serum, negative samples (lane 1 and 2), and polyclonal mouse antiserum (raised against Ng-Mip and Ng-OmpA recombinant proteins) (lane 3 and 4) as positive controls, respectively. Sera of gonorrhoea infected patients, urethritis and DGI (lane 5-6, and 7-8), respectively were used as primary antibodies. MW: Molecular Size PageRuler Prestained Protein Ladder, Fermentas.

3.6 Serum bactericidal activity

A total of 6 sera samples from infected patients with gonorrhoea were tested. In particular, 2 of them were obtained from patients with disseminated gonococcal infection, and the others 4 were collected from patients with urethritis.

The results revealed that human sera had bactericidal activity against both homologous and heterologous strains including sera from DGI patients. Moreover, all of the sera samples tested, showed bactericidal activity against *Δmip* or *ΔompA* gonococci.

Notably, both polyclonal mouse sera arised against recombinant protein Ng-OmpA and Ng-Mip proteins, respectively, showed serum bactericidal activity against the wild type strains. No serum bactericidal activity was observed against knockout strains.

4. Conclusions

Gonorrhoea is a global health concern with increasing infection rates worldwide. Disease rates remain disproportionately high in less-developed countries and continue to increase in Western-style industrialized countries, while increased antimicrobial resistance has reduced treatment options (Tapsall JW, 2008). The economic burden of gonorrhoea is also quite substantial, and further compounded by downstream effects such as HIV transmission and Pelvic Inflammatory Disease (PID) (Tapsall JW, 2008). Effective measures for the control of STDs require the introduction of complex, integrated multi-disciplinary programs (O'Reilly KR et al, 1996; Tapsall JW, 2001). The laboratory-based aspects of these integrated disease control approaches include enhanced diagnosis, identification of disease transmission patterns and optimisation of treatment options.

In Italy, little is known regarding the microbiological features of circulating gonococci. A study was undertaken from 2003-2007 to explore these issues. Taking into consideration the reported incidence of recorded cases over the study period, the isolates in this study represent 80% of all notified cases and therefore should provide a correct picture of the current situation.

Our results revealed that *N. gonorrhoeae* strains were associated with heterosexuals and were identified predominantly among Italian men with an average age of 33 years. Approximately 10% of the patients with gonorrhoea were also co-infected with HIV-1. This rate of co-infection is similar to that described in other European countries (Boyer CB et al, 2006) although an underestimate of cases should be taken into account.

Interestingly, more than 90% of gonorrhoea infections among the heterosexual patients were due to drug resistant *N. gonorhoeae* strains.

Worthy of note is also the high percentage of antibiotic resistant strains which could further complicate the disease outcome especially for HIV positive patients. Notably, a large percentage of plasmid-mediated resistance was observed among gonococci circulating in our country. The presence of mobile elements responsible for the resistance to penicillin and tetracycline underline the possibility of transfer to other strains. For these antibiotics a large percentage of strains with reduced susceptibility that could increase the number of resistant strains in the next future was also observed.

Gonorrhoea differs from most other curable STDs because of the extent of antibiotic resistance limiting the ability to provide effective treatment and thus the control of the disease. The continued emergence of resistance in this organism is a threat to therapies and therefore close monitoring of the susceptibility to drugs to determine the prevalence of resistance and to detect any change in antibiotic resistance at an early stage is necessary in order to promptly change the antibiotic treatment protocol .

Genotypic analyses of our isolates revealed the presence of a large cluster circulating in Turin. Isolates identified as ST661 were predominantly associated with heterosexual transmission within the Turin province. A large component of strains resistant to 3 antibiotics belonged to this ST suggesting that in this region, the resistance may have arisen by clonal dissemination rather than by horizontal transfer of resistant genes. The persistence of such a large cluster might indicate that the nature of the sexual network and/or sexual behaviour of the people might contribute to the spread of such strains. Alternatively, isolates belonging to this genotype, might have a fitness advantage over other strains enabling it to be dominant in the sexual network. This cluster is important due to the drug resistant

phenotype of the strains which could have negatively influenced the outcome of cases, particularly complicating treatment among HIV positive patients.

The high number of singleton STs found in this study, could be explained in two different ways: first of all due to high recombination rates in gonococci and the strong selective pressure for change to evade immune system; secondly it may be a consequence of sub optimal diagnostic procedures, ineffective partner tracing, local and recent emergence of new STs, imported strains via sexual tourist or foreign travel, all of which need to be further evaluated in the next few years.

Several reports have described the main characteristics concerning the immunity to *N*. gonorrhoeae. In particular, immunity during gonococcal infection is complicated by antigenic variation of the pathogen and, as a consequence, the lack of immune memory. Moreover gonococci have the ability to survive inside macrophages providing a further means to overcome host surveillance and promote persistence of infection. Ng-MIP and Ng-OmpA proteins, two novel virulence factors identified in *N. gonorrhoeae*, have been demonstrated to be involved in intra macrophages survival, disclosing new insights into gonococcal pathogenesis. Notably, these proteins are surface-exposed, conserved among Gram negative bacteria, and involved in invasion of mammalian cells as well as in resistance to serum bactericidal activity (Jeannin P et al, 2002).

Based on this evidence the presence and the gene conservation of these proteins in a selected group of Italian isolates have been investigated. The strains analysed were associated with different clinical pictures such as urethritis or DGI. They were also chosen according to different

microbiological characteristics: serovars; susceptibility to the antibiotic tested; unrelated STs, or strains belonging to the same STs, (most of them belonging to ST661).

Interestingly, despite their surface exposure, Ng-Mip revealed a high degree of amino acid sequence homology; a 100% of homology was also found for Ng-OmpA These findings support the possibility to employ them as vaccine components. Purified, recombinant Ng-MIP and Ng-OmpA proteins were also recognized by sera samples from infected patients with gonorrhoea. Both of the sera from patients with local or systemic infections were able to react with these proteins in a western blot analysis The ability of antibodies elicited against Ng-MIP and Ng-OmpA to kill bacteria has also been considered on both polyclonal mouse sera and sera collected from patients against heterologous and homologous strains.

These results suggest that a serum produced against only one of these two proteins was able to kill gonococci with the same efficacy as a serum collected from a patient with a systemic or a localized gonorrhoea disease. Together with the high gene sequence conservation among strains, the serum bactericidal activity of specific anti-Mip and anti-OmpA proteins, design the latter as good and potential vaccine candidates.

Further investigations will be performed to completely characterize the immune response against gonococci considering that cases of repeated infections have been described in the literature. However, it has been demonstrated that, depending on the site of infection, different levels of protective immunity could be generated (Hedges SR et al, 1999), leading to new concepts on mucosal or systemic immunizations.

5. Acknowledgments

I would like to express my gratitude to all of the persons that have contributed in various ways to the present Thesis.

I especially wish to express my sincere thanks to :

Dr. Paola Stefanelli

Dr. Cecilia Fazio

Dr. Arianna Neri

Dr. Anna Carannante.

I also thank Tonino Sofia for editorial assistance.

6. References

Adler MW, Meheust AZ. **Epidemiology of sexually transmitted infections and human immunodeficiency virus in Europe**. *J Eur Acad Dermatol Venereol* 2000, 14: 370-7.

Anzala AO, Simonsen JN, Kimani J. **Acute sexually transmitted infections increases human immunodeficiency virus type 1 plasma viremia increase plasma type 2 cytokines and decrease cell CD4 cell count**. *J Infect Dis* 2000, 182 (2): 459-66.

Apicella MA, Shero M, Jarvis GA. **Phenotypic variation in epitope expression of the *Neisseria gonorrhoeae* lipo-oligosaccharide**. *Infect Immun* 1987, 55: 1755-61.

Apicella MA, Ketterer M, Lee FK. **The pathogenesis of gonococcal urethritis in men: confocal and immunoelectron microscopic analysis of urethral exudates from men infected with *Neisseria gonorrhoeae***. *J Infect Dis* 1996, 173 (3): 636-46

Bauer FJ. Rudel T, Stein M. **Mutagenesis of *Neisseria gonorrhoeae* porin reduces invasion in epithelial cells and enhances phagocyte responsiveness**. *Mol Microbiol* 1999, 31: 903-13.

Bhat KS, Gibbs CP, Barrera O. **The opacity proteins of *Neisseria gonorrhoeae* MS11 are encoded by a family of 11 complete genes**. *Mol Microbiol* 1992, 6 (8): 1073-6.

Bolan G, Ehrhardt AA, and Wasserheit JN. **Gender perspectives and STDs**, p 117-127. In K Holmes, Mardh PA. *Sexually transmitted diseases* 1999, 3rd ed. McGraw-Hill, NY.

Boslego JW, Tramont EC, Chung DG. **Efficacy trial of a parenteral gonococcal pilus vaccine in man**. *Vaccine* 1991, 9 (3):154-62.

Boulton IC, Gray-Owen SD. **Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes**. *Nat Immunol* 2002, 3: 229-36.

Boyer CB, Shafer MA, Pollak LM. **Sociodemographic markers and behavioural correlates of sexually transmitted infections in a non clinical sample of adolescent and young adult women**. *J Infect Dis* 2006, 194: 307-15.

Bouvet JP, Belèc R, Pirés R. **Immunoglobulin G antibodies in human vaginal secretions after parenteral vaccination**. Infect Immun 1994, 62 (9): 3957-61.

Burch CL, Danaher RJ, and Stein DC **Antigenic variation in *Neisseria gonorrhoeae*. Production of multiple lipo-oligosaccharides**. *J Bacteriol* 1997, 179: 982-6.

Chesson HW, Dee TS, Aral SO: **AIDS mortality may have contributed to the decline in syphilis rates in the United States in 1990s**. *Sex Transm Dis* 2003, 30(5): 419-24.

Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2002 supplement: Gonococcal Isolate Surveillance Project (GISP) annual report 2002 Centre for Disease Control and Prevention, 2003.

Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, Atlanta GA: US Department of Health and Human Services, 2004.

Dal Conte I, Starnino S, Di Perri G. **Disseminated gonococcal infection in an immune-competent patient caused by an imported *Neisseria gonorrhoeae* multidrug-resistant strain**. *J Clin Microbio*l 2006, 44 (10): 3833-4.

Danielsson D. **Gonorrhoea diagnostic and therapeutic strategies in the era of resistance to antibiotics**. Semin Dermatol 1990, 9(2): 109-16.

Deguchi T, Yasuda M, Nakano M. **Quinolone-resistant *Neisseria gonorrhoeae*: correlation of alterations in the *gyrA* subunit of DNA gyrase and the *par*C subunit of topoisomerase IV with antimicrobial susceptibility profiles**. *Antimicrobial Agents and Chemother* 1996, 40: 1020-3.

Dehio C, Gray-Owen SD, Meyer TF. **Host cell invasion by pathogenic Neisseriae** p 61-69. In TA Oelschlaeger and J Hacker (ed), subcellular biochemistry, vol 33 **Bacterial invasion into eukaryotic cells**. *Plenum Publishers* 2000, NY.

Demarco de Hormaeche, Jessop H and Senior K. **Gonococcal variants selected by growth *in vivo* or in vitro have antigenically different LPS**. *Microb Pathog* 1988, 4: 289-97.

Densen P, Zollinger WD, Gulati S and Rice PA **Antibodies against *Neisseria gonorrhoeae* lipo-oligosaccharide antigens stimulate neutrophil chemotaxis.** In J Poolman Zanen, T Beuvery (ed) Gonococci and meningococci. *Kluwer Academic Publishers Dordrecht* 1998, The Netherlands.

Edwards JL, Apicella MA. **The molecular mechanisms used by *Neisseria gonorrhoeae* to initiate infection differ between men and women**. *Clin Microbiol Rev* 2004, 17 (4): 965-81.

Fanghanel J, Fischer G. **Insights into the catalytic mechanism of peptidyl prolil cis/trans isomerases**. *Front Biosci* 2004, 9:3453-78.

Fenton KA and Lowndes CM. **Recent trends in the epidemiology of sexually transmitted infections in the European Union**. *Sex Transm Infect* 2004; 80: 255-63.

Finney M. PFGE 2.5.9-2.5.17 *In* Ansubel FM, **Current protocols in molecular biology**, vol 1 *Current protocols* 1993, greene-Wiley NY.

Fischer G, Bang H, Ludwig B. **Mip protein of *Legionella pneumophila* exhibits peptidyl-prolyl-cis/trans isomerase (PPIase) activity**. *Mol Microbiol* 1992, 6: 1375-83.

Gerbase AC, Rowley JT, Mertens TE. **Global epidemiology of sexually transmitted disease** *Lancet* 1998; 351 (3): 2-4.

Giardina PC, Apicella MA, Gibson B. **Antigenic mimicry in *Neisseria* species** p55-65. In H. Brade, SM OpaI, SN Vogel, and DC Morrison. *Endotoxin in health and disease* 1999, Marcel Dekker Inc., NY.

Gill M, Jyamohan J, Lessing MP. **Naturally occurring PIA/PIB hybrids of *Neisseria gonorrhoeae*** *FEMS Microbiol Lett* 1994, 119 (1-2): 161-6.

Giuliani M, Suligoi B, The STD Surveillance Working Group. **Sentinel surveillance of sexually transmitted diseases in Italy**. *Euro Surveill* 1998, 3(6): 53-8.

Gotschlich EC, Seiff ME, Blake MS. **Porin protein of *Neisseria gonorrhoeae*: cloning and gene structure** *PNAS* 1987, 84 (22): 8135-9.

Goering RV. **Molecular epidemiology of nosocomial infection: analysis of chain restriction fragments patterns in PFGE.** *Infect Control Hosp Epidem* 1993, 14: 595-600.

Grassmè H, Ireland RM, Van Putten JP. **Gonococcal opacity proteins promote bacterial entry-associated rearrangements of the epithelial cell actin cytoskeleton**. *Infect Immun* 1996, 64 (5): 1621-30.

Grassmè H, Gulbins E, Brenner B. **Acidic sphingomyelinase mediates entry of *N. gonorrhoeae* in non-phagocytic cell**. *Cell* 1997, 91(5): 605-15.

Gray-Owen SD and Blumberg RS. **CEACAM-1 contact dependent control of immunity**. *Nature* 2006, 6: 433-47.

Gronow S, Brade H. **Lipopolysaccharide biosynthesis: which steps do bacteria need to survive?** *J Endotoxin Res* 2001, 7:3-23.

Griffiss JM, Lammel CJ, Wang J. *Neisseria gonorrhoeae* **coordinately uses Pili and Opa to activate HEC-1 cell microvilli which causes the engulfment of the gonococci.** *Infect Immun* 1999, 67 (7): 3469-80.

Haines KA, Yeh L, Blake MS. **Effects of protein I of** *Neisseria gonorrhoeae* **on neutrophil activation: generation of diacylglycerol from phosphatidylcholine via a specific phospholipase C is associated with exocytosis**. *J Cell Biol* 1991, 114: 433-42.

Hajishengallis G, Nikolova E and Russell MW. **Inhibition of** *Streptococcus mutans* **adherence to saliva-coated hydroxyapatite by human secretory immunoglobulin A (S-IgA) antibodies to cell surface protein antigenI/II: reversal by IgA1 protease cleavage**. *Infect Immun* 1992; 60:5057-64.

Hamilton HL, Dillard JP. **Natural trasformation of** *Neisseria gonorrhoeae* **from DNA donation to homologous recombination**. *Mol Microbiol* 2006, 59 (2): 376-85.

Handsfield HH, McCutchan JA, Corey L. **Evaluation of new anti-infective drug for treatment of uncomplicated gonorrhoea in adults and adolescents. Infectious disease society of America and the Food and Drug Administration**. *Clin Infect Dis* 1999, 15 (1): S123-30.

Harry TC, Black PD. **Unilateral gonococcal opthalmia without genital infection: an unusual presentation in an adult**. *Int J STD AIDS* 2005, 16(1): 78-9.

Harvey HA, Jennings MP, Campbell CA. **Receptor-mediated endocytosis of** *Neisseria gonorrhoeae* **into primary human urethral epithelial cells: the role of the asialoglycoprotein receptor** *Mol Microbiol* 2001, 42: 659-672.

Harvey HA, Swords WE, and Apicella MA. **The mimicry of human glycolipids and glycosphingolipids in the lipo-oligosaccharides of pathogenic *Neisseria* and *Haemophilus***. *J Autoimmun* 2001, 16:257-62.

Hauck CR and Meyer TF. **The lysosomal/phagosomal membrane protein h-lamp-1 is a target of the IgA1 protease of *Neisseria gonorrhoeae*** 1997; *FEBS Lett*, 405:86-90.

Hedges SR, Mayo MS, Mestecky J, Hook III EW limited local and systemic antibody response to *Neisseria gonorrhoeae* **during uncomplicated genital infections**. *Infec Immun* 1999, 67: 3937-46.

Hoggerhout P, Donders EMLM, Van Gaans-van. **Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein**. *Infect Immun* 1995, 63: 3473-8.

Hughes G, Catchpole M. **Surveillance of sexually transmitted infections in England and Wales**. *Euro Surveill* 1998, 3 (6): 61-65.

Ison CA, Tekki N and Gill MJ. **Detection of *TetM* determinant in *Neisseria gonorrhoeae* Sex Transm Dis** 1993 Nov-Dic, **20**: 329-33.

Jarvis G, Griffiss JM. **Human IgA1 blockade of IgG-initiated lysis of *Neisseria meningitides* is a function of antigen-binding fragment binding to polysaccharide capsule** *J Immunol* 1991, 147:1962-7.

Jonsson AB, Ilder V, Falker P. **Sequence changes in the pilus subunit lead to tropism variation of *Neisseria gonorrhoeae* in human tissue**. *Mol Microbiol* 1994, 13 (3): 403-16.

Kallstrom H, Liszewiski, Atkinson JP. **Membrane cofactor protein (MCP or CD46) is a cellular pilus receptor for pathogenic *Neisseria***. *Mol Microbiol* 1997, 25 (4): 639-47.

Kallstrom H, Blackmer Gill D, Albiger B. **Attachment of *Neisseria gonorrhoeae* to the cellular pilus receptor CD46: identification of**

domains important for bacterial adherence. *Cell Microbiol* 2001, 3 (3): 133-43.

Kenney CD, Cornelissen CN. **Demonstration and characterization of a specific interaction between gonococcal transferring binding protein A and TonB**. *J Bacteriol* 2002, 184 (22): 6138-45.

Kilian M, Reinholdt J, Lomholt H. **Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence** *APMIS* 1996, 104: 321-38.

Knapp JS, Tam MR, Nowinski KK. **Serological classification of *Neisseria gonorrhoeae* with use of monoclonal antibodies to gonococcal outer membrane protein I.** *J Infect Dis*1984, 150: 44-8.

Knepper B, Heuer I, Meyer TF. **Differential response of human monocytes to *Neisseria gonorrhoeae* variants expressing pili and opacity proteins**. *Infect Immun* 1997, 65 (10): 4122-9.

Koebnik R, Locher KP, Van Gelder P. **Structure and function of bacterial of outer membrane proteins barrel in a nutshell**. *Mol Microbiol* 2000, 37(2): 239-53.

Kohler R, Fanghanel J, Konig B. **Biochemical and functional analyses of the Mip protein: influence of the N-terminal half and of peptidylprolyl isomerise activity on the virulence of *Legionella pneumophila***. *Infect Immun* 2003, 71: 4389-97.

Laga M, Manoka A, Kivuvu M. **Non-ulcerative sexually transmitted disease at risk factors for HIV-1 transmission in women: results from a cohort study**. *AIDS* 1993, 7(1): 95-102.

Laemmli UK. **Cleavage of structural proteins during the assembly of the head of bacteriophage T4**. *Nature* 1970, 227: 680-5.

Leuzzi R, Serino L, Scarselli M. **Ng-MIP, a surface exposed lipoprotein of *Neisseria gonorrhoeae*, has a peptidyl-prolil *cis/trans* isomerase**

(PPIase) activity and is involved in persistence in macrophages. *Mol Microbiol* 2005, 58 (3): 669-81.

Looveren Van M , Ison CA, Ieven M. **Evaluation of discriminatory power of typing methods for** *Neisseria gonorrhoeae***.** *J Clin Microb* 1999, 37: 2183-8.

Lundemose AG, Kay JE and Pearce JH. *Chlamydia trachomatis* **Mip-like protein has peptidyl-prolil** *cis/trans* **isomerase activity that is inhibited by FK506 and rapamycin and is implicated in initiation of Chlamydia infection**. *Mol Microbiol* 1993, 7: 777-83.

MacDonald N, Mailman T, Desai S. **Gonococcal infections in newborns and adolescent**. *Adv Exp Med Biol*. 2008, 609:108-30.

Mandrell RE, Griffiss JM and Macher B. **Lipooligosaccharides (LOS) of** *Neisseria gonorrhoeae* **and** *Neisseria meningitidis* **have components that are immunologically similar to precursors of human blood group antigens**. *J Exp Med* 1988, 168: 107-26.

Mansa B and Kilian M. **Retained antigen-binding activity of Fab-α fragments of human monoclonal immunoglobulin A1 (IgA1) cleaved by IgA1 protease**. *Infect Immun* 1986, 52:171-4.

Martich GD, Boujoukos AJ, Suffredini AF. **Response of a man to endotoxin.** *Immunobiol* 1993, 187:403-16.

Martin IM, Ison CA, Aanensen DM. **Rapid sequence based identification of gonococcal transmission clusters in a large metropolitan area**. *J Infect Dis* 2004,15 (189):1497-505.

Massari P, Ram S, Macleod H. **The role of porins in neisserial pathogenesis and immunity**. *TRENDS in Microbiology* 2003, 11 (2): 87-93.

Mavroidi A, Tzouvelekis LS, Kiriakis KP. **Multi-drug resistant strains of** *Neisseria gonorrhoeae* **in Greece**. *Antimicrobial Agents and Chemother* 2001, 45: 2651-4.

McQuillen DP, Gulati S and Rice PA. **Complement-mediated bacterial killing assays**.
Methods in enzimology 1994, 236:137-47.

Mei Hu, Nandi S, Davies C. **High-Level Chromosomally Mediated Tetracycline Resistance in** *Neisseria gonorrhoeae* **Results from a Point Mutation in the** *rpsJ* **Gene Encoding Ribosomal Protein S10 in Combination with the** *mtrR* **and** *penB* **Resistance Determinants**. *Antimicrobial Agents and Chemother* 2005, **49**: 4327-34.

Mertz AJ, Enns CA, So M. **Type IV pili of pathogenic Neisseria elicit cortical plaque formation in epithelial cells**. *Mol Microbiol* 1999, 32 (6): 1316-32.

Meyer TF, Phlner and Putten van JP. **Biology of the pathogenic** *Neisseria*. *Curr Top Microbiol Immunol* 1994, 192: 283-317.

Moro A, Ruiz-Cabello F, Fernandez-Cano A. **Secretion by** *Tripanosoma cruzi* **of a peptidyl-prolil** *cis/trans* **isomerise involved in cell infection**. *EMBO J* 1995, 14: 2483-90.

Mosleh IM, Huber LA, Steinlein P. *Neisseria gonorrhoeae* **porin modulates phagosome maturation.** *J Biol Chem* 1998, 273: 35332-8.

Moslow JN, Slutsky AM and Arbeit RD. **Application of PFGE to molecular epidemiology. Diagnostic molecular microbiology: principles and applications**. *American Society for Microbiology* p 563 Washington, DC.

Muller A, Gunther D, Dux F. **Neisserial porin (PorB) causes rapid calcium influx in target cells and induces apoptosis by the activation of cysteine proteases**. *EMBO J* 1999, 19: 5332-43.

Nassif X, Pujol C, Morand P. **Interaction of pathogenic *Neisseria* with host cells. Is it possible to assemble the puzzle?** *Mol Microbiol* 1999, 32(6): 1124-32.

Ng LK, Carballo M, Dillon JA. **Differentiation of *Neisseria gonorrhoeae* isolate requiring praline, citrulline and uracil by plasmid content serotyping and pulsed field gel electrophoresis**. *J Clin Microbiol* 1995, 33:1039-41.

O'Reilly KR, Piot P. **International perspectives on individual and community approaches to the prevention of sexually transmitted disease and human immunodeficiency virus infection**. *J Infect Dis*. 1996, 174 (S214-S222).

O'Rourke M, Ison CA, Renton M ***Opa*-typing: a high-resolution tool for studying the epidemiology of gonorrhoea**. *Mol Microbiol* 1985, 17: 865-875.

Palmer HM, Leeming JP and Turner A. **Investigation of an outbreak of ciprofloxacin-resistant *Neisseria gonorrhoeae* using a simplified *opa*-typing method**. *Epidemiol Infect* 2001, 126: 219-24.

Palmer HM, Leeming JP and Turner A. **A multiplex polymerase chain reaction to differentiate β-lactamase plasmids of *Neisseria gonorrhoeae***. *J Antimicrob and Chemother* 2000; 45: 777-782.

Panchaud C, Singh S, Feivelson D. **Sexually transmitted among adolescents in developed countries**. *Fam Plann Perspect* 2000, 32: 24-32.

Pautsch A, Schulz GE. **Structure of the outer membrane protein A transmembrane domain**. *Nat Struct Biol* 1998, 5 (11): 1013-7

Poh CL, Lou QC. **Subtyping of *Neisseria gonorrhoeae* auxotype, serovar groups by PFGE**. *J Med Microbiol* 1993, 38: 366-70.

Poolman JT. **Bacterial outer membrane protein vaccine. The meningococcal example.** *Adv Med Exp Biol* 1996, 397: 73-7.

Prasadarao NV, Blom AM, Villoutreix BO. **A novel interaction of outer membrane protein A with C4b binding protein mediates serum resistance of *Escherichia coli* K1**. *J Immunol* 2002, 169: 6352-60.

Ram S, Sharma AK, Simpson SD. **A novel sialic acid binding site on factor H mediates serum resistance of sialylated *Neisseria gonorrhoeae*.** *J Exp Med* 1998, 187: 743-52.

Rudel T, Boxberger HJ and Meyer TF. **Pilus biogenesis and epithelial cell adherence of Neisseria *gonorrhoeae* pilC double Knock-out mutants**. *Mol Microbiol* 1995, 17:107-71.

Sandstrom E and Danielsson D **Serology of *Neisseria gonorrhoeae*. Classification by co-agglutination**. *Acta Pathol Microbiol Scand* 1980, 88: 27-28.

Schmidt B, Rahfeld J, Schierhorn A. **A homodimer represents an active species of the peptidyl-prolyl cis/trans isomerase FKBP25mem from *Legionella pneumophila***. *FEBS Lett* 1994, 352: 185-90.

Shafer WM and Rest RF. **Interaction of gonococci with phagocytic cells**. *Annu Rev Microbiol* 1989, 43: 121-145.

Schneider H, Griffis JM, Boslego JW. **Expression of paragloboside-like lipooligosaccharide may be a necessary component of gonococcal pathogenesis in men**. *J Exp Med* 1991, 174 (6):1601-5.

Serino L, Nesta B, Leuzzi R **Identification of a new OmpA-like protein in *Neisseria gonorrhoeae* involved in the binding to human epithelial cells and *in vivo* colonization**. *Mol Microbiol* 2007, 64 (5): 1391-403.

Snyder LA, Butcher SA, and Saunders NJ. **Comparative whole genome analyses reveal over 100 putative phase variable genes in the pathogenic *Neisseria spp***. *Microbiology* 2001, 147. 2321-2332.

Song W, Ma L, Chein W. **Role of lipo-oligosaccharide in *opa-*independent invasion of *Neisseria gonorrhoeae* into human epithelial cells**. *J Exp Med* 2000, 191: 949-59.

Sonntag I, Schwarz H, Hirota Y. **Cell envelope and shape of *Escherichia coli*: multiple mutants missing the outer membrane lipoprotein** and other outer membrane proteins. *J Bacteriol* 1978, 136: 280-5.

Sparling PF, Elkins C, Wyrick PB **Vaccine for bacterial sexually transmitted infections: A realistic goal?** *PNAS* 1994, 91: 2456-63.

Sparling PF. **Biology of *Neisseria gonorrhoeae*** p. 433-499 Sexually transmitted diseases 1999, 3rd ed. McGraw-Hill, New York.

Swanson J. **Studies on gonococcus infection XIV. Cell wall protein differences among color/opacity colony variants of *Neisseria gonorrhoeae***. *Infect Immun* 1978, 21: 292-302.

Tapsall JW. **Antimicrobial resistance in *Neisseria gonorrhoeae***. WHO, Geneva, Switzerland (2001). www.who.int/entity/drugresistance/Antimicrobial_resistance_in_Neisseria_gonorrhoeae.pdf.

Tapsall JW. **Antibiotic resistance in *Neisseria gonorrhoeae***. *Clin Infect Dis* 2005, 41(4); S263-S268.

Tapsall JW. **Antibiotic resistance in *Neisseria gonorrhoeae* is diminishing available treatment options for gonorrhoeae-some possible remedies.** *Expert Rev Anti Infect Ther* 2008, *in press*

Tenover FC, Arbeit RD, and Goering RV. **How to select and interpret molecular strain typing methods for epidemiological studies of bacterial infections: a review for healthcare epidemiologist. Molecular Typing Working Group of the Society for Healthcare Epidemiology of *America***. *Infect Control Hosp Epidemiol* 1997, 18: 426-39.

Turner A, Gough KR, Leeming JP. **Molecular epidemiology of *TetM* genes in *Neisseria gonorrhoeae*.** *Sex Transm Inf* 1999, 75: 60-66.

Van der Heyden JH, Catchpole MA, Paget WJ (European Study Group). **Trends in gonorrhoea in nine western European countries, 1991-6.** *Sex Transm Infect* 2000, 76: 110-6.

Van der Ley, Heckels JE, Virji M. **Topology of outer membrane porins in pathogenic *Neisseria spp*.** *Infect Immun* 1991, 59:2963-71.

Van Putten JP, Duensing TD, Carlson J. **Gonococcal invasion of epithelial cells driven by PIA a bacterial ion channel with GTP binding properties.** *J Exp Med* 1988, 188 (5): 941-52.

Van Putten JP, Duensing TD, Cole RL. **Entry of Opa+ gonococci into Hep-2 cells requires concerted action of glycosaminoglycans, fibronectin and integrin receptors.** *Mol Microbiol* 1998, 29: 369-379.

Viscidi RP, Demma JC, Gu J. **Comparison of sequencing of the *por* gene and typing of the *opa* gene for discrimination of *Neisseria gonorrhoeae* strains from sexual contacts.** *J Clin Microbiol* 2000, 38: 4430-8.

World Health Organization (WHO) Global programme on AIDS. **An overview of selected curable sexually transmitted diseases.** Geneva: WHO, 1995: 3.

Ward H, Ison CA, Day SE. **A prospective social and molecular investigation of gonococcal transmission.** *Lancet* 2000, 356 (9254):1812-7.

7. Original paper

Disseminated Gonococcal Infection in an Immunocompetent Patient Caused by an Imported *Neisseria gonorrhoeae* Multidrug-Resistant Strain

Ivano Dal Conte,[1] Stefania Starnino,[2] Giovanni Di Perri,[1] and Paola Stefanelli[2]*

STI Clinic, Department of Infectious Diseases, Amedeo di Savoia Hospital, University of Turin, Turin, Italy,[1] and Department of Infectious, Parasitic, and Immune-Mediated Diseases, Istituto Superiore di Sanità, Rome, Italy[2]

We herein report the microbiological features of a *Neisseria gonorrhoeae* strain isolated from an immunocompetent patient with disseminated gonococcal infection (DGI). The strain expressed the IA/IB serovar; was resistant to penicillin, tetracycline, and ciprofloxacin; and had presumably been acquired in Southeast Asia. To date, this is the first case reported in our country of DGI due to an imported multidrug-resistant strain.

CASE REPORT

A 48-year-old man reported to the emergency department of Turin General Hospital with generalized malaise, pyrexia, nausea, and vomiting. His past medical history revealed hypertension and a recent trip to Thailand where he had engaged several times in sexual intercourse with local sex workers. Physical examination revealed a temperature of 39.8°C, a blood pressure of 190/100 mm Hg, a faint mitral holosystolic murmur, and diffuse hemorrhagic skin rash. There were no signs of meningeal involvement. The patient was admitted to the general medicine ward with suspected bacterial endocarditis. Upon admission, biochemistry was normal, and the white blood cell count was 14,100 (83.9% polymorphonuclear leukocytes, 7.3% lymphocytes, and 8.5% monocytes). The erythrocyte sedimentation rate was 78 mm/h, and the C-reactive protein level was 5.9 mg/dl. Chest X rays and transthoracic echocardiography were normal. Gram-negative diplococci were identified by API-NH (bioMerièux, France) as *Neisseria gonorrhoeae* in blood culture. Urethral specimens were negative; no throat or rectum specimens were collected. Serology for human immunodeficiency virus and syphilis was negative, and the patient was not immunocompromised. Treatment with 2 g oxacillin four times daily intravenously and 80 mg gentamicin twice daily was commenced. Three days later, the patient was afebrile. Following blood culture results, the patient was treated with 2 g ceftriaxone intramuscularly daily for 10 days. At discharge and follow-up, no clinically relevant problems were observed. The gonococcal strain was sent to the laboratory of the Istituto Superiore di Sanità for complete phenotypic and genotypic characterization. After growth on GC agar plates supplemented with 2% Isovitalex (Oxoid) and incubated at 37°C in 5% CO_2 for 18 to 20 h, a serological assay by coagglutination reaction was performed using two monoclonal antibodies (Phadebact GC serovar test; Boule Diagnostic AB, Sweden) directed against epitopes of the IA and IB porin

proteins. The isolate showed a reactivity against both porin proteins, thus resulting in a hybrid serovar (IA/IB).

Antimicrobial susceptibility testing was carried out using a panel of five antibiotics (penicillin, tetracycline, spectinomycin, ciprofloxacin [Cip], and ceftriaxone) by the E test method (ABbiodisk, Sweden) according to the manufacturer's instructions. The antimicrobial susceptibility breakpoints were those defined by the CLSI (3). A nitrocefin chromogenic test (Oxoid) was used to detect the presence of β-lactamase production. The strain was resistant to three of the five antibiotics tested. In particular, the MICs were >32 μg/ml for penicillin, 24 μg/ml for tetracycline, and 4 μg/ml for Cip. MICs for ceftriaxone and spectinomycin were 0.002 and 6 μg/ml, respectively.

Molecular analysis of the target genes involved in each antibiotic resistance mechanism was performed. In particular, after total bacterial DNA extraction with a QIAGEN DNA extraction kit, a multiplex PCR assay was used to differentiate β-lactamase plasmids using the following primers: BL1 (5′-TACTCAATCGGTAATTGGCT), BL2 (5′-CACCTATAAATCTCGCAAGC), BL3 (5′-CCATAGTGTTGAGTATTGCGAA), and BL4 (5′-TCATTCGTGCGTTCTAGGA) (10, 11, 16). Detection of a plasmid named "Toronto/Rio" confirmed the presence of a penicillinase-producing *N. gonorrhoeae* isolate, a common feature of most gonococci responsible for disseminated gonococcal infection (DGI) (8, 9).

The tetracycline resistance mobile elements were detected by PCR using three primers, UF (5′-CTCGAACAAGAGGAAAGC), AR (5′-GCATTCCACTTCCCAAC), and DR (5′-TGCAGCAGAGGGAGG), as previously described (10, 11, 16). The high level of tetracycline resistance (MIC of 24 μg/ml) was due to a plasmid defined as an "American type plasmid," the most frequently detected plasmid in tetracycline-resistant *N. gonorrhoeae* isolates (16).

To investigate the presence of amino acid substitutions on the two target genes (*gyrA* and *parC*) known to be involved in resistance to ciprofloxacin (2), sequence analyses of the quinolone resistance determinant regions were performed after amplification with primers *gyr*A1 (5′-CGGCGCGTACTGTACGCGATGCA), *gyr*A2 (5′-ATGTCTGCCAGCATTTCATGTGAGA), *par*C1 (5′-ATGGCGATATGGGTTTGAC), and *par*C2 (5′-GGACAACAGCAATTCCGCAA) (15). The anal-

* Corresponding author. Mailing address: Department of Infectious, Parasitic, and Immune-Mediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, Rome, Italy. Phone: 390649902126. Fax: 390649387112. E-mail: paolaste@iss.it.

ysis of sequences revealed the presence of amino acid substitutions $Asp_{86} \rightarrow Asn$ in the *parC* gene and $Ser_{91} \rightarrow Phe$ and $Asp_{95} \rightarrow Gly$ in the *gyrA* gene. These changes have already been described in the literature as being correlated to the Cip-resistant phenotype (1).

———————

N. gonorrhoeae, the causative agent of the homonymous sexually transmitted disease, has the human genital tract as its reservoir. However, it has also numerous other presentations both inside and outside the genitourinary tract (14). In recent years, despite the worldwide increase in genital gonococcal infections, complicated cases such as DGI have rarely been reported (6, 9, 14). The clinical manifestations of DGI include skin disorders, arthritis, endocarditis (rarely occurring in 1 or 2% of cases), or other localized infections (1, 7–9, 13, 14). The pathogenesis of DGI has been associated with both microbial and host factors. The patient's complement deficiency is considered one of the most important causes favoring the course of disease (12). In this report, we investigated a case of DGI in an immunocompetent patient with suspected bacterial endocarditis. The *N. gonorrhoeae* isolate was completely characterized for its microbiological features.

Considering the history of the patient, infection very likely occurred in Southeast Asia; the isolated strain showed multiple-antibiotic resistance, and this is particularly significant, since *N. gonorrhoeae* isolates with these properties have not been frequently described in cases of DGI. Moreover, the American type plasmid, responsible for tetracycline resistance, although frequent in Africa, has rarely been described in Thailand.

Two main comments arise from the case described. First, despite a widespread increase in the rates of reproductive tract infections, this case is evidence of a low attention to sexually transmitted infections, since a sexually transmitted pathogen was not initially suspected despite the history of travel and sexual exposure in a country with a high prevalence of sexually transmitted infections. Travel to such areas must be regarded as a risk factor for acquiring gonorrhea.

Second, since the last series of DGI described (7–9), many changes have occurred in the laboratory diagnosis of gonococcal infection. Now, molecular epidemiology can efficiently clarify transmission dynamics and geographic patterns; it may also be helpful in exploring bacterial virulence factors and drug resistance. The infection had probably been contracted in an area where drug resistance is a well-recognized issue. However, besides sharing common features with the majority of gonococci responsible for DGI, identified as penicillinase-producing *N. gonorrhoeae* (10, 11), and the presence of the most commonly identified plasmid in tetracycline-resistant *N. gonorrhoeae* strains (16), the imported strain is characterized by the presence of an IA/IB serotype. Hybrid *N. gonorrhoeae* strains expressing both IA and IB porin proteins are quite uncommon among clinical isolates (4, 5). However, the most characterized hybrid strains are those described previously by Gill et al. (5). Those authors hypothesized two possible reasons for the rare occurrence of a hybrid form of porin: first, there might be a reduced fitness of such strains since they could be more easily recognized and killed by bactericidal antibodies in patients

with a previous gonococcal infection; second, a hybrid form of this porin could be responsible for its altered function on the surface of the gonococcus. A possible selective antibiotic pressure, for instance, penicillin and tetracycline, could also contribute to the appearance and survival of such hybrid gonococcal strains (5). To date, this is the first case of DGI due to a multidrug-resistant strain reported in Italy. The spread of gonococci with multiple-antibiotic resistance could partially explain the occurrence of DGI without any particularly altered host factor. The characterization of molecular changes associated with gonococcal resistance in DGI is essential to provide rapid advice for clinical management of cases. In fact, multidrug-resistant DGI can be fatal if not recognized and treated correctly. Moreover, the sporadic occurrence of DGI highlights the need for a reconsideration of diagnostic and epidemiologic criteria to include the search for *N. gonorrhoeae* in clinical samples in order to avoid misidentification and thus a delay in appropriate treatment.

REFERENCES

1. **Abe, H., T. Nishimura, Y. Norose, T. Aoto, H. Ohzuka, and H. Ohkuni.** 2003. Frequency of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in 19 clinical isolates of *Neisseria gonorrhoeae* in Tokyo in 2002. J. Infect. Chemother. **9:**310–313.
2. **Arreaza, L., C. Salcedo, B. Alcala, S. Berron, E. Martin, and J. A. Vazquez.** 2003. Antibiotic resistance of *Neisseria gonorrhoeae* in Spain: trends over the last two decades. J. Antimicrob. Chemother. **51:**153–156.
3. **CLSI.** 2005. Performance standards for antimicrobial susceptibility testing. 15th informational supplement, vol. 5. CLSI, Wayne, Pa.
4. **Cooke, S. J., K. Jolley, C. A. Ison, H. Young, and J. E. Heckels.** 1998. Naturally occurring isolates of *Neisseria gonorrhoeae*, which display anomalous serovar properties, express PIA/PIB hybrid porins, deletions in PIB or novel PIA molecules. FEMS Microbiol. Lett. **162:**75–82.
5. **Gill, M. J., J. Jayamohan, M. P. Lessing, and C. A. Ison.** 1994. Naturally occurring PIA/PIB hybrids of *Neisseria gonorrhoeae*. FEMS Microbiol. Lett. **119:**161–166.
6. **Holmes, K. K., P. J. Weisner, and A. H. Pedersen.** 1971. The gonococcal arthritis-dermatitis syndrome. Ann. Intern. Med. **75:**470–471.
7. **Mehrany, K., J. M. Kist, W. J. O'Connor, and D. J. DiCaudo.** 2003. Disseminated gonococcemia. Int. J. Dermatol. **42:**208–209.
8. **Mirmiran, R., J. L. Hembree III, W. P. Reed, and D. Jessup.** 2000. Disseminated gonococcal infection: a case of beta-lactamase-producing *Neisseria gonorrhoeae*. J. Am. Podiatr. Med. Assoc. **90:**273–275.
9. **O'Brien, J. P., D. L. Goldenberg, and P. A. Rice.** 1983. Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms. Medicine (Baltimore) **62:**395–406.
10. **Pagotto, F., A. T. Aman, L. K. Ng, K. H. Yeung, M. Brett, and J. A. Dillon.** 2000. Sequence analysis of the family of penicillinase-producing plasmids of *Neisseria gonorrhoeae*. Plasmid **43:**24–34.
11. **Palmer, H. M., J. P. Leeming, and A. Turner.** 2000. A multiplex polymerase chain reaction to differentiate beta-lactamase plasmids of *Neisseria gonorrhoeae*. J. Antimicrob. Chemother. **45:**777–782.
12. **Petersen, B. H., T. J. Lee, R. Snyderman, and G. F. Brooks.** 1979. *Neisseria meningitidis* and *Neisseria gonorrhoeae* bacteremia associated with C6, C7, or C8 deficiency. Ann. Intern. Med. **90:**917–920.
13. **Shetty, A., D. Ribeiro, A. Evans, and S. Linnane.** 2004. Gonococcal endocarditis: a rare complication of a common disease. J. Clin. Pathol. **57:**780–781.
14. **Spencer, S. E., and M. C. Bash.** 2006. Extragenital manifestations of *Neisseria gonorrhoeae*. Curr. Infect. Dis. Rep. **8:**132–138.
15. **Tanaka, M., H. Nakayama, M. Haraoka, T. Saika, I. Kobayashi, and S. Naito.** 2000. Susceptibilities of *Neisseria gonorrhoeae* isolates containing amino acid substitutions in GyrA, with or without substitutions in ParC, to newer fluoroquinolones and other antibiotics. Antimicrob. Agents Chemother. **44:**192–195.
16. **Turner, A., K. R. Gough, and J. P. Leeming.** 1999. Molecular epidemiology of tetM genes in *Neisseria gonorrhoeae*. Sex. Transm. Infect. **75:**60–66.